Nothing Special   »   [go: up one dir, main page]

EP0745070A1 - Pharmaceutical piperazine compounds - Google Patents

Pharmaceutical piperazine compounds

Info

Publication number
EP0745070A1
EP0745070A1 EP95908314A EP95908314A EP0745070A1 EP 0745070 A1 EP0745070 A1 EP 0745070A1 EP 95908314 A EP95908314 A EP 95908314A EP 95908314 A EP95908314 A EP 95908314A EP 0745070 A1 EP0745070 A1 EP 0745070A1
Authority
EP
European Patent Office
Prior art keywords
piperazinedione
benzylidene
group
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95908314A
Other languages
German (de)
French (fr)
Inventor
Stephen James Brocchini
Justin Stephen Bryans
Adrian John Folkes
Christopher John Latham
Julie Elizabeth Brumwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenova Ltd
Original Assignee
Xenova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenova Ltd filed Critical Xenova Ltd
Publication of EP0745070A1 publication Critical patent/EP0745070A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to compounds useful as inhibitors of plasminogen activator inhibitor (PAI) , to their preparation and to pharmaceutical and veterinary compositions containing them.
  • PAI plasminogen activator inhibitor
  • Plasminogen activators are serine proteases which control the activation of the zymogen, plasminogen, to the active enzyme plasmin. Plasmin is important in a number of physiological and pathological processes including fibrinolysis, tissue remodelling, tumour growth and metastasis.
  • the glycoprotein plasminogen activator inhibitor (PAI) is an endogenous fast-acting inhibitor of PA activity. PAI is a member of the serpin family and is synthesised by a variety of cells including endothelial cells. An imbalance between PAs and PAI contributes to a number of pathological conditions including haemostasis, inflammation, tumour growth and metastasis.
  • the present invention provides a diketopiperazine of formula (A) :
  • R x and R 2 which may be the same or different, is: (I) X, or a phenyl group which is substituted by X, C(0)X, OC(0)CH 2 X, OCH 2 CH 2 X, CH 2 X, CONH(CH 2 ) n X, 0(CH 2 ) n CH(OH) (CH 2 ) ⁇ X or
  • R x and R 2 is a phenyl group optionally substituted by one or more groups independently selected from halogen, nitro, methoxy, NHC(0)R 12 , C0 2 H, 0(CH 2 ) n N(R 12 R 13 ) , CH 2 Y(CH 2 ) n N(R 12 R 13 ) , C x -C 4 alkyl and (CH 2 ) n C(0)0R 12 ;
  • X is a naphthyl group or a five- or six-membered saturated or unsaturated heterocyclic group containing one or more heteroatoms, which heteroatoms may be the same or different and are independently selected from 0, N and S; the heteroatom(s) when nitrogen being optionally substituted by hydrogen, methyl, oxygen, tertiary-butyloxycarbonyl, - (CH 2 ) complicatCH 2 OH or S0 2 Me; the heterocyclic ring being optionally substituted by halogen, Me, MeS, phenyl, 0(CH 2 ) n NR 12 R 13 , -N(R 12 ) (CH 2 ) n N(R 12 R 13 ) , - (CH 2 ) n N(R 12 R 13 ) or -0(CH 2 ) n O(CH 2 ) n N(R 12 R 13 ) , or the heterocyclic ring optionally containing one or more carbonyl groups and being optionally fused to a
  • Z is a C 3 -C 6 cycloalkyl group
  • R 12 , R 13 and R 14 which may be the same or different, are hydrogen or C-_-C 6 alkyl;
  • R 15 and R 16 which may be the same or different, are hydrogen or alkyl, or R 1S and R 16 form, together with the nitrogen atom to which they are attached, a 5- or 6- membered heterocyclic group;
  • W is hydrogen or a phenyl group
  • V is a phenyl group optionally substituted by one or more groups independently selected from nitro, alkoxy,
  • a C 1 -C 6 alkyl group is, for example, a C 1 -C 4 alkyl group, such as a methyl, ethyl, propyl, i-propyl, n-butyl, sec-butyl or tert-butyl group.
  • a halogen may be F, Cl, Br or I.
  • free rotation may occur at room temperature about the single bonds connecting substituents R 1 and R 2 to the double bonds at positions 3 and 6 of the piperazine-2, 5-dione ring.
  • At least one of R 1 and R 2 which may be the same or different, is chosen from a naphthyl group
  • X is a five- or six-membered saturated or unsaturated heterocyclic group containing one or two heteroatoms, which heteroatoms may be the same or different and are independently selected from 0, N and S, the heteroatom(s) when nitrogen being optionally substituted by hydrogen, methyl, oxygen, tertiary-butyloxycarbonyl, -(CH 2 ) n CH 2 OH or S0 2 Me, the heterocyclic ring being optionally substituted by hydrogen, halogen, methyl, MeS, phenyl, 0(CH 2 ) n NR 12 R 13 , 0(CH 2 ) n N(R 12 R 13 ) or -0(CH 2 ) n O(CH 2 ) n N(R 12 R 13 ) ; the heterocyclic ring optionally containing one or more carbonyl groups, and being optionally fused to
  • the said other of R j ⁇ and R 2 is a phenyl group substituted at the 4-position by -0(CH 2 ) n N(R 12 R 13 ) , -CH 2 Y(CH 2 ) n N(R 12 R 13 ) or - (CH 2 ) n NR 14 C(0) (CH 2 ) felicitNR 12 R 13 .
  • one of R-_ and R 2 is X, a phenyl group substituted by X, -CH 2 X, -OCH 2 CH 2 X,
  • R and R 2 is a phenyl group optionally substituted at the 4-position by
  • X is particularly preferred for X to be a furyl, imidazolyl, pyrrolyl, thienyl, morpholinyl, piperidinyl or isoquinolyl grou .
  • R 12 and R 13 which may be the same or different, are hydrogen or C 1 -C 3 alkyl and n is an integer of value 1 or 2.
  • one of R x and R 2 is a phenyl group which is substituted by X, CO(X) , OCO(0)CH 2 X, OCH 2 CH 2 X, CH 2 X or which is fused to a group X, wherein X is a five- or six-membered heterocyclic ring containing one or two heteroatoms which may be the same or different, independently selected from O, N and S, the heteroatom(s) when nitrogen being optionally substituted by methyl, and the heterocyclic ring being optionally fused to a benzene ring.
  • R x and R 2 is a phenyl group substituted by CH 2 NR 12 R 13 , OC(0) (CH 2 ) n Z, CH(0R 12 ) (0R 13 ) , (CH 2 ) ⁇ NR 14 C(0) (CH 2 ) m N(R 12 R 13 ) ; wherein R 12 , R 13 and R 14 , which may be the same or different, are independently selected from hydrogen or C 1 -C 3 alkyl; Z is a C 5 or C 6 cycloalkyl group; and m and n are, independently, integers having the values 1, 2 or 3.
  • R 12 , R 13 and R 14 which may be the same or different, are independently selected from hydrogen and C- ⁇ -C ⁇ alkyl; Z is a cyclopentyl group; and m and n are, independently, integers having the values of 1 or 2.
  • one of R 1 and R 2 is a phenyl group optionally substituted by one or more groups independently selected from chloro, nitro, methoxy, HCOR 12 , C0 2 H and 0(CH 2 ) n NR 12 R 13 ; R 12 and R 13 , which may be the same or different, are independently selected from hydrogen or methyl and n is an integer having the value 1 or 2.
  • W is a phenyl group optionally substituted by one of more groups independently selected from nitro, methoxy and 0(CH 2 ) n NMe 2 and n is an integer having the value 1, 2,3 or 4.
  • n is 1 or 2.
  • one of R ⁇ and R 2 is a phenyl group optionally substituted by NHAc or methoxy.
  • R x and R 2 is cyclohexyl and the other is a phenyl group optionally substituted by NHC(0)R 12 .
  • one of R and R 2 is cyclohexyl and the other is a phenyl group optionally substituted by NHC(0)Me.
  • R 3 is C ⁇ C-. alkyl or (CH 2 ) n C(0)OR 12 ;
  • R 12 is hydrogen or Ci-Cj alkyl and n is an integer of value 1 or 2.
  • R 3 is methyl or CH 2 C(0)OR 12 and R 12 is hydrogen or methyl.
  • diketopiperazines have been disclosed as having utility as bioactive agents.
  • Yokoi et. al in J. Antibiotics vol XLI No. 4, pp 494-501 (1988) describe structure-cytotoxicity relationship studies on a series of diketopiperazines related to neihumicin, .a compound obtained from the micro-organism Micromonospora neihuensis, Kamei et al in J. Antibiotics vol XLIII No. 8, 1018-1020 disclose that two diketopiperazines, designated piperafizines A and B, have utility as potentiators of the cytotoxicity of vincristine. Examples of specific compounds of formula A are as follows. The compound numbering is adhered to in the rest of the specification:
  • 1657 (3Z,6Z) -3- (4-Aminomethylbenzylidene) -6- (4- methoxybenzylidene) -2,5-piperazinedione.
  • 1693 (3Z,6Z) -3- (1-methanesulfonyl-3-indolyl)methylene-6- (4- methoxybenzylidene) -2,5-piperazinedione.
  • 5324 (3Z, 6Z) -6-Benzylidene-3- (5- (2-dimethylaminoethoxy) -2- thienylmethylene) -2,5-piperazinedione.
  • 5327 (3Z,6Z) -6-Benzylidene-3- (4- (2-dimethylaminoethoxy) -2- thienylmethylene) -2,5-piperazinedione.
  • Compounds of formula A may be prepared by a process which comprises either (i) condensing compound of formula
  • R 2 is as defined above and is optionally protected, with a compound of formula (II) :
  • Rj_ is as defined above and is optionally protected, in the presence of a base in an organic solvent; or (ii) condensing a compound of formula (I') :
  • R x is as defined above and is optionally protected, with a compound of formula (III) :
  • R 2 is as defined above and is optionally protected, in the presence of a base in an organic solvent; and, in either case (i) or (ii) , if required, removing optionally present protecting groups and/or, if desired, converting one compound of formula A into another compound of formula A, and/or, if desired, converting a compound of formula A into a pharmaceutically acceptable salt or ester thereof, and/or, if desired, converting a salt or ester into a free compound, and/or, if desired, separating a mixture of isomers of compounds of formula A into the single isomers.
  • a compound of formula A produced directly by the condensation reaction between (I) and (II) or (I') and (III) may be modified, if desired, by converting R-. into a different Rj , group.
  • R 1 comprises an ester group
  • R 1 comprises an ester group
  • R 2 includes an -OH group may be converted into a compound of formula A wherein the corresponding substituent is esterified, for example by treating with a suitable carboxylic acid in the presence of an appropriate coupling agent, acid anhydride or acid chloride in an inert solvent.
  • R 2 includes a -C0 2 H group may be converted into a compound of formula A wherein the corresponding substituent is esterified, for example by treating the carboxylic acid with a suitable C- ⁇ -Cg alkyl alcohol in the presence of 1,3- dicyclohexylcarbodiimide in an inert solvent.
  • a compound of formula A in which either or both of R x and R 2 includes a free -C0 2 H group may be converted into a compound of formula A in which the corresponding substituent is a group -C0N(R X1 R 12 ) , wherein R X1 and R 12 are as defined above, for example by treatment with ammonia or an amine in the presence of 1,3-dicyclohexylcarbodiimide in an inert solvent.
  • a compound of formula A in which either or both of R-, and R 2 includes a free -C0 2 H group may be converted into a compound of formula A wherein the corresponding substituent is a -CH 2 OH group by reduction, for example using borane in a suitable solvent such as tetrahydrofuran.
  • a compound of formula A in which either or both of R 1 and R 2 is a nitro group may be converted into a compound of formula A in which the corresponding substituent is an amino group by reduction under standard conditions, for example by catalytic hydrogenation.
  • Protecting groups for substituents on R and/or R 2 in any of the compounds of formulae (I), (I'), (II) and (III) are optionally introduced prior to step (i) or step (ii) when either or both R x and R 2 include one or more groups which are sensitive to the condensation reaction conditions or incompatible with the condensation reaction, for example a -C00H, -CH 2 0H or amino group.
  • the protecting groups are then removed at the end of the process. Any conventional protecting group suitable for the group R-, and/or R 2 in question may be employed, and may be introduced and subsequently removed by well-known standard methods.
  • the condensation reaction between compounds (I) and (II) or (I') and (III) is suitably performed in the presence of a base which is potassium t-butoxide, sodium hydride, potassium carbonate, sodium carbonate, caesium carbonate, sodium acetate, potassium fluoride on alumina, or triethylamine in a solvent such as dimethylformamide, potassium t-butoxide in t-butanol, or a mixture of t- butanol and dimethylformamide (DMF) .
  • the reaction is typically performed at a temperature from 0°c to the reflux temperature of the solvent.
  • the compounds of formula (I) may be prepared by a process comprising reacting l,4-diacetyl-2,5- piperazinedione with a compound of formula (III) as defined above, in the presence of a base in an organic solvent.
  • the compounds of formula (I') may be prepared by a process which comprises reacting l,4-diacetyl-2,5- piperazinedione with a compound of formula (II) as defined above, in the presence of a base in an organic solvent.
  • the resulting compound of formula (I) or (I') can be separated from other reaction products by chromatography.
  • reaction of 1,4-diacetyl-2, 5-piperazinedione with the compound of formula (III) or (II) is suitably performed under the same conditions as described above for the condensation between compounds (I) and (II), or (I') and (III) .
  • the substituted aldehydes of formulae (II) and (III) are known compounds or can be prepared from readily available starting materials by conventional methods.
  • the 1,4-diacetyl-2, 5-piperazinedione used as a starting material in the preparation of compounds of formula (I) may be prepared by treating 2, 5-piperazinedione (glycine anhydride) with an acetylating agent.
  • the acetylation may be performed using any conventional acetylating agent, for example acetic anhydride under reflux or, alternatively, acetic anhydride at a temperature below reflux in the presence of 4-dimethylaminopyridine.
  • Compounds of formula (I) may also be prepared by the microwave irradiation of a mixture comprising 1,4-diacetyl- 2, 5-piperazinedione, a compound of formula (III) and potassium fluoride on alumina (as base) in the absence of solvent.
  • Compounds of formula (I) may alternatively be prepared directly from 2, 5-piperazinedione (glycine anhydride) by a process which comprises treating the 2,5-piperazinedione with a mixture comprising a compound of formula (III) , sodium acetate and acetic anhydride at an elevated temperature, for example under reflux.
  • Compounds of formula (I') may be prepared by analogous processes, replacing compound (III) in each case by a compound of formula (II) .
  • Compounds of formula A may also be prepared by a process comprising the microwave irradiation of (i) a mixture comprising a compound of formula (I) as defined above, a compound of formula (II) and potassium fluoride on alumina, or (ii) a mixture comprising a compound of formula (I') a compound of formula (III) and potassium fluoride on alumina, or (iii) a mixture comprising 1,4-diacetyl-2, 5- piperazinedione, a compound of formula (II) , a compound of formula (III) and potassium fluoride on alumina.
  • the irradiation is performed in the absence of a solvent.
  • Compounds of formula (A) may also be obtained directly by a process which comprises condensing together 1,4- diacetyl-2, 5-piperazinedione, a compound of formula (II) and a compound of formula (III) in the presence of a base in an organic solvent.
  • Suitable bases, solvents and reaction conditions are as described above for the condensation reaction between, for example, compounds (I) and (II) .
  • An alternative direct process for the preparation of compounds of formula (A) comprises condensing together 2,5- piperazinedione, a compound of formula (II) and a compound of formula (III) in the presence of sodium acetate and acetic anhydride at elevated temperature, for example under reflux.
  • An alternative process for the preparation of compounds of formula (I) comprises treating a compound of formula (V) : wherein R 6 to R 10 are as defined above, X is a halogen and R' is a C J -C J alkyl group, with ammonia followed by acetic anhydride.
  • R x to R s , X and R' are as defined above, with ammonia followed by acetic anhydride.
  • X in formula (V) or (V) is typically iodine.
  • R' is, for example, a C x -C 4 alkyl group such as a methyl, ethyl, propyl, i-propyl, butyl, sec-butyl or tert-butyl group.
  • Compounds of formula (A) may be optionally washed after any of the above preparative procedures with one or more of the following: water, ethanol, ethyl acetate and diethyl ether.
  • Suitable salts include salts with pharmaceutically acceptable, inorganic or organic, acids or bases.
  • inorganic bases include ammonia and carbonates, hydroxides and hydrogen carbonates of group I and group II metals such as sodium, potassium, magnesium and calcium.
  • organic bases include aliphatic and aromatic amines such as methylamine, triethylamine, benzylamine, dibenzylamine or a- or ⁇ -phenylethylamine, and heterocyclic bases such as piperidine, 1-methylpiperidine and morpholine.
  • inorganic acids include hydrochloric acid, sulphuric acid and orthophosphoric acid.
  • organic acids include p-toluenesulphonic acid, methansulphonic acid, mucic acid and succinic acid.
  • esters include branched or unbranched, saturated or unsaturated d-Cg alkyl esters, for example methyl, ethyl and vinyl esters.
  • the diketopiperazines of formula (A) both novel and known and their pharmaceutically acceptable salts and esters (referred to hereinafter as the "present compounds") have utility as inhibitors of PAI. Elevated levels of PAI- 1, by reducing the net endogenous fibrinolytic capacity, can contribute to the pathogenesis of various thrombotic disorders including myocardial infarction, deep vein thrombosis and disseminated intravascular coagulation. The present compounds therefore can act as inhibitors of the tPA/PAI-1 interaction. The present compounds can be used in the treatment of haemostatic disorders.
  • a human or animal e.g.
  • a mammal can therefore be treated by a method comprising administration of a therapeutically effective amount of a diketopiperazine of formula (A) or a pharmaceutically or veterinarily acceptable salt thereof.
  • Tissue plasminogen activator (tPA) is used as a fibrinolytic agent in the treatment of thrombotic disorders. The efficacy of the tPA in this role may be enhanced if it is administered together with a PAI inhibitor.
  • a human or animal e.g. a mammal, can therefore be treated by a method comprising the combined administration of a therapeutically effective amount of tPA and a therapeutically effective amount of any one of the present compounds.
  • the present invention also provides products containing a diketopiperazine of formula (A) or a pharmaceutically acceptable salt or ester thereof and tPA as a combined preparation for simultaneous, separate or sequential use in the treatment of thrombotic disorders, for example where there is inappropriate PAI activity.
  • the present compound is formulated for oral or parenteral (intravenous, intramuscular or subcutaneous) administration and the tPA is formulated for intravenous administration.
  • MI myocardial infarction
  • one of the present compounds may be administered to a patient together with tPA to enhance the efficacy of the tPA treatment.
  • early re-occlusion following treatment of a patient with tPA may be prevented by the post-MI administration of one of the present compounds.
  • the compounds of formula (A) have been tested in a PAI functional assay.
  • a compound is incubated with PAI-1 prior to addition to the tPA assay system.
  • Inhibition of PAI-1 results in the production of plasmin from plasminogen.
  • plasmin cleaves the chromogenic substrate S2251 (Kabi Vitrum) producing pNA (p- nitroaniline) which is detected spectrophotometrically at 405 nm (K.Nilsson et al, Fibrinolysis (1987) .1, 163-168) .
  • the results of the assay are reported below.
  • the present compounds can be administered in a variety of dosage forms, for example orally such as in the form of tablets, capsules, sugar- or film-coated tablets, liquid solutions or suspensions or parenterally, for example intramuscularly, intravenously or subcutaneously.
  • the present compounds may therefore be given by injection or infusion.
  • the dosage depends on a variety of factors including the age, weight and condition of the patient and the route of administration. Typically, however, the dosage adopted for each route of administration when a compound of the invention is administered alone to adult humans is 0.001 to 10 mg/kg, most commonly in the range of 0.01 to 5 mg/kg, body weight. Such a dosage may be given, for example, from 1 to 5 times daily by bolus infusion, infusion over several hours and/or repeated administration. When one of the present compounds is administered in combination with tPA to adult humans, the dosage adopted for each route of administration is typically from 0.001 to 10 mg, more typically 0.01 to 5 mg per kg body weight for a compound of the invention and from 5 to 500mg administered intravenously for the tPA.
  • a suitable dosage regimen for the tPA is 100 mg given intravenously over 3 hours as follows: 10% of the total dose as an i.v. bolus over 1-2 minutes, 50% of the total dose as an infusion over 1 hour, 40% of the total dose as an infusion over the subsequent 2 hours.
  • a diketopiperazine of formula (A) or a pharmaceutically acceptable salt or ester thereof is formulated for use as a pharmaceutical or veterinary composition also comprising a pharmaceutically or veterinarily acceptable carrier or diluent.
  • the compositions are typically prepared following conventional methods and are administered in a pharmaceutically or veterinarily suitable form.
  • An agent for use as an inhibitor of PAI comprising any one of the present compounds is therefore provided.
  • the solid oral forms may contain, together with the active compound, diluents such as lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants such as silica, talc, stearic acid, magnesium or calcium stearate and/or polyethylene glycols; binding agents such as starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose, or polyvinyl pyrrolidone; disintegrating agents such as starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs, sweeteners; wetting agents such as lecithin, polysorbates, lauryl sulphates.
  • diluents such as lactose, dextrose, saccharose, cellulose, corn starch or potato starch
  • lubricants such as silica, talc, stearic acid, magnesium or calcium stearate and/or polyethylene glycols
  • Liquid dispersions for oral administration may be syrups, emulsions and suspensions.
  • the syrups may contain as carrier, for example, saccharose or saccharose with glycerol and/or mannitol and/or sorbitol.
  • a syrup for diabetic patients can contain as carriers only products, for example sorbitol, which do not metabolise to glucose or which only metabolise a very small amount to glucose.
  • the suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose or polyvinyl alcohol.
  • Suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier such as sterile water, olive oil, ethyl oleate, glycols such as propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride.
  • a pharmaceutically acceptable carrier such as sterile water, olive oil, ethyl oleate, glycols such as propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride.
  • Some of the present compounds are insoluble - 26 - in water.
  • a compound may be encapsulated within liposomes.
  • Reference Example 5 Preparation of (3Z) -l-acetyl-3- (2,6- dichlorobenzylidene) -2,5- piperazinedione l,4-Diacetyl-2, 5-piperazinedione prepared by the published procedure mentioned in Reference Example 3, was stirred in DMF with 2, 6-dichlorobenzaldehyde and triethylamine and heated to 120-130°C for l-3h. The title compound was obtained with a yield of 40%.
  • Reference Example 6 Preparation of (3Z) -l-acetyl-3- (4-
  • Example 1 Preparation of 1470 3 (Z) -1-Acetyl-3-benzylidene-2, 5-piperazinedione (one equivalent) , which is compound 18 prepared according to Reference Example 1, was treated with 1-tert- butoxycarbonylpyrrole-2-carboxaldehyde in the presence of Cs 2 C0 3 (1-1.1 equivalents) in DMF at 80-lOOoC for 1-6 hours. The title compound was obtained in 24% yield.
  • the crude product was optionally, washed with water, methanol, ethyl acetate or diethylether and optionally recrystallised from methanol as appropriate.
  • the crude product was optionally washed with water, methanol, ethyl acetate and diethylether and optionally recrystallised from acetic acid or methanol as appropriate.
  • Example 4 Preparation of 1676 l-Acetyl-3- (4-acetamidobenzylidene) -2,5- piperazinedione (one equivalent) , prepared according to Reference Example 2, was treated with cinnamaldehyde in the presence of Cs 2 C0 3 (1-1.1 equivalents) in DMF at 80-100oc for 1-6 hours. The title compound was obtained in 46% yield.
  • the 2, 5-piperazinedione derivative 14.1 was treated with the aldehyde 14.2, the groups Ar and Subst. being as specified below, in DMF in the presence of Cs 2 C0 3 at 80°C- 90°C for 2-4 hours.
  • the compounds of formula (I) listed below were prepared:
  • Hydrochloride salts of the following compounds of formula (I) were prepared by bubbling HC1 gas through a solution of the corresponding free base in tetrahydrofuran (THF) at room temperature. The salt was recovered in the yield indicated.
  • Hydrochloride salts of the following compounds of formula (I) were prepared by bubbling HCl gas through a solution of the corresponding free base in hot DMF. The salt was recovered in the yield indicated.
  • 5043.HCl the hydrochloride salt of 5043, was prepared by bubbling HCl gas through a solution of 5043 in MeOH.
  • 5057.HCl the salt of 5057, was prepared by bubbling HCl gas through a solution of 5057 in THF following by recrystallisation from MeOH.
  • Tablets each weighing 0.15 g and containing 25 mg of a compound of the invention can be manufactured as follows: Composition for 10,000 tablets compound of the invention (250 g) lactose (800 g) corn starch (415 g) talc powder (30 g) magnesium stearate (5 g)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A diketopiperazine of formula (A), wherein one or both of R1 and R2, which may be the same or different, is: (I) X, or a phenyl group which is substituted by X, C(O)X, OC(O)CH2X, OCH2CH2X, CH2X, CONH(CH2)nX, O(CH2)nCH(OH) (CH2)nX or (a) or which is fused to a group X; (II) a phenyl group substituted by CH2NR12R13, OC(O) (CH2)nZ, CH(OR12)(OR13), (CH2)nNR14C(O) (CH2)mNR12R13 or O(CH2)nCH(OH) (CH2)nN(R12R13); (III) a group CH=C(W)V; or (IV) a cyclohexyl group; and where appropriate, the other of R1 and R2 is a phenyl group optionally substituted by one or more groups independently selected from halogen, nitro, methoxy, NHC(O)R12, CO2H, O(CH2)nN(R12R13) and CH2Y(CH2)nN(R12R13); R3 is C1-C4 alkyl or (CH2)nC(O)OR12; Y is O or S; Z is a C3-C6 cycloalkyl group; W is hydrogen or a phenyl group; and the pharmaceutically acceptable salts and esters thereof having activity as inhibitors of plasminogen activator inhibitor.

Description

PHARMACEUTICAL PIPERAZINE COMPOUNDS The present invention relates to compounds useful as inhibitors of plasminogen activator inhibitor (PAI) , to their preparation and to pharmaceutical and veterinary compositions containing them.
Plasminogen activators (Pas) are serine proteases which control the activation of the zymogen, plasminogen, to the active enzyme plasmin. Plasmin is important in a number of physiological and pathological processes including fibrinolysis, tissue remodelling, tumour growth and metastasis. The glycoprotein plasminogen activator inhibitor (PAI) is an endogenous fast-acting inhibitor of PA activity. PAI is a member of the serpin family and is synthesised by a variety of cells including endothelial cells. An imbalance between PAs and PAI contributes to a number of pathological conditions including haemostasis, inflammation, tumour growth and metastasis.
The present invention provides a diketopiperazine of formula (A) :
wherein one or both of Rx and R2, which may be the same or different, is: (I) X, or a phenyl group which is substituted by X, C(0)X, OC(0)CH2X, OCH2CH2X, CH2X, CONH(CH2)nX, 0(CH2)nCH(OH) (CH2)πX or
or which is fused to a group X;
(II) a phenyl group substituted by CH2NR12R13,
OC(O) (CH2)nZ, CH(OR12) (OR13) , (CH2)nNR14C(0) (CH2)mNR12R13, - CH2NR12- (CH2)nNRlsRls or 0(CH2)nCH(OH) (CH2)nN(R12R13) ;
(III) a group CH=C(W)V; or (IV) a cyclohexyl group; and where appropriate, the other of Rx and R2 is a phenyl group optionally substituted by one or more groups independently selected from halogen, nitro, methoxy, NHC(0)R12, C02H, 0(CH2)nN(R12R13) , CH2Y(CH2)nN(R12R13) , Cx-C4 alkyl and (CH2)nC(0)0R12;
X is a naphthyl group or a five- or six-membered saturated or unsaturated heterocyclic group containing one or more heteroatoms, which heteroatoms may be the same or different and are independently selected from 0, N and S; the heteroatom(s) when nitrogen being optionally substituted by hydrogen, methyl, oxygen, tertiary-butyloxycarbonyl, - (CH2)„CH2OH or S02Me; the heterocyclic ring being optionally substituted by halogen, Me, MeS, phenyl, 0(CH2)nNR12R13, -N(R12) (CH2)nN(R12R13) , - (CH2)nN(R12R13) or -0(CH2)nO(CH2)nN(R12R13) , or the heterocyclic ring optionally containing one or more carbonyl groups and being optionally fused to a benzene ring, which benzene ring is optionally substituted by 1 or 2 C^-Cg alkoxy groups; Y is 0 or S ;
Z is a C3-C6 cycloalkyl group;
R12, R13 and R14, which may be the same or different, are hydrogen or C-_-C6 alkyl; R15 and R16, which may be the same or different, are hydrogen or alkyl, or R1S and R16 form, together with the nitrogen atom to which they are attached, a 5- or 6- membered heterocyclic group;
W is hydrogen or a phenyl group; V is a phenyl group optionally substituted by one or more groups independently selected from nitro, alkoxy,
O(CH2)nNR12R13, and NR12R13; and m and n are each, independently, 0 or an integer having the value 1, 2, 3 or 4; or a pharmaceutically acceptable salt or ester thereof. A C1-C6 alkyl group is, for example, a C1-C4 alkyl group, such as a methyl, ethyl, propyl, i-propyl, n-butyl, sec-butyl or tert-butyl group.
A halogen may be F, Cl, Br or I. In compounds of formula A free rotation may occur at room temperature about the single bonds connecting substituents R1 and R2 to the double bonds at positions 3 and 6 of the piperazine-2, 5-dione ring.
In one embodiment at least one of R1 and R2, which may be the same or different, is chosen from a naphthyl group,
X, a phenyl group substituted by X, C(0)X, OC(0)CH2X,
OCH2CH2X, or CH2X and a phenyl group which is fused to a group X; wherein X is a five- or six-membered saturated or unsaturated heterocyclic group containing one or two heteroatoms, which heteroatoms may be the same or different and are independently selected from 0, N and S, the heteroatom(s) when nitrogen being optionally substituted by hydrogen, methyl, oxygen, tertiary-butyloxycarbonyl, -(CH2)nCH2OH or S02Me, the heterocyclic ring being optionally substituted by hydrogen, halogen, methyl, MeS, phenyl, 0(CH2)nNR12R13, 0(CH2)nN(R12R13) or -0(CH2)nO(CH2)nN(R12R13) ; the heterocyclic ring optionally containing one or more carbonyl groups, and being optionally fused to a benzene ring; and the other of Rx and R2 is a phenyl group optionally substituted at the 2, 3 or 4-position by CH2 R12R13, (CH2)nNR14C(O) (CH2)„ 12 ι3, halogen, nitro, - HC(0)R12, -0(CH2)nN(R12R13) or -CH2Y(CH2)nN(R12R13) wherein Y is 0 or S. In a particularly preferred series of compounds the said other of Rj^ and R2 is a phenyl group substituted at the 4-position by -0(CH2)nN(R12R13) , -CH2Y(CH2)nN(R12R13) or - (CH2)nNR14C(0) (CH2)„NR12R13.
In a further embodiment one of R-_ and R2 is X, a phenyl group substituted by X, -CH2X, -OCH2CH2X,
0(CH2)nCH(OH)CH2X or ' wherein X is a 5
or 6-membered saturated or unsaturated heterocyclic group as defined above which is optionally substituted and optionally fused to a benzene ring, for instance a pyridyl, imidazolyl, furyl, pyrrolyl, pyrrolidinyl, thienyl, piperazinyl, piperidinyl, morpholinyl, quinolyl, isoqUinolyl or indolyl group; and the other of R and R2 is a phenyl group optionally substituted at the 4-position by
-0(CH2)nN(R12R13) , -CH2Y(CH2)nN(R12R13) or
- (CH2)nNR14C(0) (CH2)m R12R13. In this embodiment it is particularly preferred for X to be a furyl, imidazolyl, pyrrolyl, thienyl, morpholinyl, piperidinyl or isoquinolyl grou .
In a further embodiment, R12 and R13, which may be the same or different, are hydrogen or C1-C3 alkyl and n is an integer of value 1 or 2. In a yet further embodiment one of Rx and R2 is a phenyl group which is substituted by X, CO(X) , OCO(0)CH2X, OCH2CH2X, CH2X or which is fused to a group X, wherein X is a five- or six-membered heterocyclic ring containing one or two heteroatoms which may be the same or different, independently selected from O, N and S, the heteroatom(s) when nitrogen being optionally substituted by methyl, and the heterocyclic ring being optionally fused to a benzene ring.
In another embodiment one of Rx and R2 is a phenyl group substituted by CH2NR12R13, OC(0) (CH2)nZ, CH(0R12) (0R13) , (CH2)πNR14C(0) (CH2)mN(R12R13) ; wherein R12, R13 and R14, which may be the same or different, are independently selected from hydrogen or C1-C3 alkyl; Z is a C5 or C6 cycloalkyl group; and m and n are, independently, integers having the values 1, 2 or 3.
In a further embodiment R12, R13 and R14, which may be the same or different, are independently selected from hydrogen and C-^-C^ alkyl; Z is a cyclopentyl group; and m and n are, independently, integers having the values of 1 or 2.
In a yet further embodiment one of R1 and R2 is a phenyl group optionally substituted by one or more groups independently selected from chloro, nitro, methoxy, HCOR12, C02H and 0(CH2)nNR12R13; R12 and R13, which may be the same or different, are independently selected from hydrogen or methyl and n is an integer having the value 1 or 2. In another embodiment one of Rx and R2 is a group CH=C( )V, W is a phenyl group optionally substituted by one of more groups independently selected from nitro, methoxy and 0(CH2)nNMe2 and n is an integer having the value 1, 2,3 or 4.
In a further embodiment n is 1 or 2. In a yet further embodiment one of R^ and R2 is a phenyl group optionally substituted by NHAc or methoxy.
In another embodiment one of Rx and R2 is cyclohexyl and the other is a phenyl group optionally substituted by NHC(0)R12. In a further embodiment one of R and R2 is cyclohexyl and the other is a phenyl group optionally substituted by NHC(0)Me.
In a further embodiment R3 is C^C-. alkyl or (CH2)nC(0)OR12; R12 is hydrogen or Ci-Cj alkyl and n is an integer of value 1 or 2.
In a yet further embodiment R3 is methyl or CH2C(0)OR12 and R12 is hydrogen or methyl.
Certain diketopiperazines have been disclosed as having utility as bioactive agents. Yokoi et. al in J. Antibiotics vol XLI No. 4, pp 494-501 (1988) describe structure-cytotoxicity relationship studies on a series of diketopiperazines related to neihumicin, .a compound obtained from the micro-organism Micromonospora neihuensis, Kamei et al in J. Antibiotics vol XLIII No. 8, 1018-1020 disclose that two diketopiperazines, designated piperafizines A and B, have utility as potentiators of the cytotoxicity of vincristine. Examples of specific compounds of formula A are as follows. The compound numbering is adhered to in the rest of the specification:
1926 (3Z, 6Z) -3-Benzylidene-6- (4-imidazolyl)methylene-2, 5- piperazinedione. 1930 (3Z, 6Z) -3-Benzylidene-6- (4- (1-imidazolyl)benzylidene) -
2,5-piperazinedione.
1929 (3Z,6Z) -3-Benzylidene-6- (4- (1- imidazolylmethyl)benzylidene) -2, 5-piperazinedione.
1959 (3Z, 6Z) -3,Benzylidene-6- (4- (2-dimethylaminoethoxy) -3- methoxybenzylidene) -2,5-piperazinedione hydrochloride.
1927 (3Z,6Z) -3-Benzylidene-6- (4- (5- methylimidazolyl) )methylene-2, 5-piperazinedione. 1921 (3Z,6Z) -3-Benzylidene-6- (4- dimethylaminocinnamylidene) -2,5-piperazinedione. 1976 (3Z, 6Z) -3- (4- (3-Dimethylaminopropoxy)benzylidene) -6- (4- (1-imidazolyl)benzylidene-2, 5-piperazinedione. 1910 (3Z,6Z) -3-Benzylidene-6- (4- (2- imidazolylethoxy)benzyliden ) -2,5-piperazinedione. 1923 (3Z, 6Z) -3-Benzylidene-6- (4-nitrocinnamylidene-2, 5- piperazinedione.
1657 (3Z,6Z) -3- (4-Aminomethylbenzylidene) -6- (4- methoxybenzylidene) -2,5-piperazinedione. 1693 (3Z,6Z) -3- (1-methanesulfonyl-3-indolyl)methylene-6- (4- methoxybenzylidene) -2,5-piperazinedione.
1886 (3Z,6Z)-3- (4-Methoxybenzylidene) -6- (4- phthalimidoacetoxybenzylidene) -2,5-piperazinedione.
1922 (3Z, 6Z) -3-Benzylidene-6- (γ-phenylcinnamylidene) -2, 5- piperazinedione.
1618 (3Z,6Z) -3- (1-tert-butoxycarbonyl-3-indolyl)methylene-
6- (2-thenylidene) -2, 5-piperazinedione.
1560 (3Z,6Z) -3- (2, 6-Dichlorobenzylidene) -6- (1-tert- butoxycarbonyl-3-indolyl)methylene-2,5-piperazinedione. 1950 (3Z, 6Z) -3-Benzylidene-6- (4- (2-dimethylaminoethoxy) -3- methoxycinnamylidene) -2, 5-piperazinedione.
1975 (3Z,6Z) -3- (4- (3-Dimethylaminopropoxy)benzylidene) -6-
(4- (1-imidazolylmethyl)benzylidene) -2, 5-piperazinedione.
1983 (3Z, 6Z) -3-Benzylidene-6- (4-N-methyl-N- (4- (N- methylpiperidinyl) ) aminomethylbenzylidene-2, 5- piperazinedione.
1509 (3Z,6Z) -3-Benzylidene-6- (3-indolylmethylene) -2,5- piperazinedione.
1542 (3Z,6Z) -3- (2, 6-Dichlorobenzylidene) -6- (3- furylmethylene) -2, 5-piperazinedione.
1545 (3Z,6Z) -3- (3-Indolylmethylene) -6- (4- methoxybenzylidene) -2, 5-piperazinedione. -
1507 (3Z,6Z) -3- (4-Methoxybenzylidene) -6- (2- (1- tertbutoxycarbonyl)pyrrolyl)methylene-2, 5-piperazinedione.
1506 (3Z,6Z) -3- (4-Methoxybenzylidene) -6- (3- (1-tert- butoxycarbonyl) indolyl)methylene-2, 5-piperazinedione.
1471 (3Z,6Z) -3-Benzylidene-6- (3- (1-tert- 5 butoxycarbonyl) indolyl)methylene-2, 5-piperazinedione.
1474 (3Z,6Z) -3- (4-Methoxybenzylidene) -6- (2- thienylmethylene) -2, 5-piperazinedione.
1476 (3Z,6Z) -3- (4-Methoxybenzylidene) -6- (3-furylmethylene)
2,5-piperazinedione. 10 1672 (3Z, 6Z) -3- (Acetamidobenzylidene) -6- cyclohexylmethylene-2, 5-piperazinedione.
1676 (3Z,6Z) -3- (4-Acetamidobenzylidene) -6-cinnamylidene-
2,5-piperazinedione.
1891 (3Z,6Z) -3-Benzylidene-6- (diethoxymethylbenzylidene) - 15 2,5-piperazinedione.
1982 (3Z, 6Z) -3-Benzylidene-6- (4- (N-methyl-N- (2- dimethylaminoethyl) aminomethylbenzylidene-2,5- piperazinedione hydrochloride.
1884 (3Z,6Z) -3-Benzylidene-6-cyclohexylmethylene-2, 5- 20. piperazinedione.
1845 (3Z,6Z) -3- (4-Acetamidobenzylidene) -6- (3,4- methylenedioxybenzylidene) -2,5-piperazinedione.
1950 (3Z, 6Z) -3-benzylidene-6- (4- (2-dimethylaminoethoxy) -3- methoxycinnamylidene) -2, 5-piperazinedione. 1718 (3Z,6Z) -3- (2-Indolylmethylene) -6- (4- methoxybenzylidene) -2,5-piperazinedione.
1808 (3Z, 6Z) -3-Benzylidene-6- (3,4- methylenedioxybenzylidene) -2, 5-piperazinedione. 1809 (3Z,6Z) -3- (4-Methoxybenzylidene) -6- (3,4- methylenedioxybenzylidene) -2,5-piperazinedione.
1470 (3Z, 6Z) -3-Benzylidene-6- (2- (1- tertbutoxycarbonyl)pyrrolyl)methylene-2,5-piperazinedione.
5023 (3Z,6Z) -3- (4-Dimethylaminomethylbenzylidene) -6- (4- (3- dimethylaminopropoxy)benzylidene-2, 5-piperazinedione.
5026 (3Z,6Z) -3- (4- (3-Dimethylaminopropoxy)benzylidene) -6-
(4- (1-imidazolyl)methylbenzylidene) -2, 5-piperazinedione.
5030 (3Z,6Z)-3-(4- (3-Dimethylaminopropoxy)benzylidene) -6-
(4- (1-imidazolyl)benzylidene) -2, 5-piperazinedione. 5367 (2- (4- ( (3Z,6Z) -6- (4- (3-
Dimethylaminopropoxy)benzylidene) -2,5-dioxo-3- piperazinylidene)methylbenzoyl) -1,2,3,4- tetrahydroisoquinoline.
5386 N- (2- (1,2,3,4-Tetrahydro-2-isoquinolyl)ethyl) -4- ( (3Z, 6Z) -6- (4- (3-dimethylaminopropoxy)benzylidene) -2, 5- dioxo-3-piperazinylidene)methylbenzamide.
5397 N- (4- (l,2,3,4-Tetrahydro-2-isoquinolyl)butyl) -4-
( (3Z, 6Z) -6- (4- (3-dimethylaminopropoxy)benzylidene) -2,5- dioxo-3-piperazinylidene)methylbenzamide. 5027 (3Z, 6Z) -6- (4- (3-Dimethylaminopropoxy)benzylidene-3- (4- pyridylmethylene) -2, 5-piperazinedione.
5028 (3Z, 6Z) -6- (4- (3-Dimethylaminopropoxy)benzylidene) -3-
(3-pyridylmethylene) -2, 5-piperazinedione. 5041 (3Z, 6Z) -6- (4- (3-Dimethylaminopropoxy)benzylidene) -3- furfurylidene-2, 5-piperazinedione.
5042 (3Z,6Z) -6- (4- (3-Dimethylaminopropoxy)benzylidene) -3- (3-Thenylidene) -2, 5-piperazinedione. 5046 (3Z, 6Z) -6- (4- (3-Dimethylaminopropoxy)benzylidene) -3- (2-Thenylidene) -2, 5-piperazinedione.
5052 (3Z,6Z) -6- (4- (3-Dimethylaminopropoxy)benzylidene) -3- (3-Furylmethylene) -2,5-piperazinedione.
5188 (3Z,6Z) -6- (4- (3-Dimethylaminopropoxy)benzylidene) -3- (2-Naphthylmethylene) -2, 5-piperazinedione.
5200 (3Z,6Z) -6- (4- (3-Dimethylaminopropoxy)benzylidene) -3- (1-Naphthylmethylene) -2, 5-piperazinedione. 5032 (3Z, 6Z) -6-Benzylidene-3- (4- (3-dimethylamino-2- hydroxypropoxy)benzylidene) -2, 5-piperazinedione. 5040 (3Z,6Z) -6-Benzylidene-3- (4- (2-hydroxy-3- morpholinopropoxy)benzylidene) -2, 5-piperazinedione. 5057 (3Z,6Z) -6-Benzylidene-3- (4- (2-hydroxy-3- (1- imidazolyl)propoxy)benzylidene) -2, 5-piperazinedione.
5043 (3Z,6Z) -6-Benzylidene-3- (4- (2-hydroxy-3- (4- (2- hydroxyethyl) -1-piperazinyl)propoxy)benzylidene) -2, 5- piperazinedione.
5062 (3Z, 6Z) -6- (4- (2-Dimethylaminoethoxy)benzylidene) -3- (3- furylmethylene) -2, 5-piperazinedione.
5071 (3Z, 6Z) -6- (4- (2-Dimethylaminoethoxy)benzylidene) -3- (3- thenylidene) -2, 5-piperazinedione.
5072 (3Z, 6Z) -6- (4- (2-Dimethylaminoethoxy)benzylidene) -3- (5- methylthio-2-thenylidene) -2, 5-piperazinedione.
5054 (3Z, 6Z) -6-Benzylidene-3- (4- (2- morpholinoethoxy)benzylidene) -2, 5-piperazinedione.
5055 (3Z, 6Z) -6-Benzylidene-3- (4- (2- (1- imidazolyl)ethoxy)benzylidene)2,5-piperazinedione.
5053 (3Z, 6Z) -6-Benzylidene-3- (4- (2- (1- pyrrolidinyl) ethoxy)benzylidene) 2,5-piperazinedione.
5069 (3Z,6Z) -6- (4- (2-
Dimethylaminoethoxymethyl)benzylidene) -3- (3-thenylidene) -
2,5-piperazinedione.
5077 (3Z,6Z) -6- (4- (2- Dimethylaminoethoxymethyl)benzylidene) -3- (3- furylmethylene) -2,5-piperazinedione.
5074 (3Z, 6Z) -6- (4-Dimethylaminoacetamidomethyl benzylidene) -3- (3-thenylidene) -2, 5-piperazinedione.
5079 (3Z,6Z) -3- (2-Bromobenzylidene) -6- (4- dimethylaminoacetamidomethylbenzylidene) -2,5- piperazinedione.
5081 (3Z, 6Z) -6- (4-Dimethylaminoacetamidomethylbenzylidene)
3- (3-furylmethylene) -2, 5-piperazinedione.
5061 (3Z,6Z) -6-Benzylidene-3- (4- dimethylaminoacetamidomethylbenzylidene) -2,5- piperazinedione.
5073 (3Z,6Z) -6- (4- (2-
Dimethylaminoethylthiomethyl)benzylidene) -3- (3- furylmethylene) -2, 5-piperazinedione. 5078 (3Z,6Z) -6- (4- (2-
Dimethylaminoethylthiomethyl)benzylidene) -3- (3- thenylidene) -2,5-piperazinedione.
1912 (3Z,6Z) -6-Benzylidene-3- (4- dimethylaminoacetamidoaminomethylbenzylidene) -2,5- piperazinedione.
5324 (3Z, 6Z) -6-Benzylidene-3- (5- (2-dimethylaminoethoxy) -2- thienylmethylene) -2,5-piperazinedione. 5327 (3Z,6Z) -6-Benzylidene-3- (4- (2-dimethylaminoethoxy) -2- thienylmethylene) -2,5-piperazinedione.
5335 (3Z, 6Z) -6-Benzylidene-3- (5- (2-dimethylaminoethyl) -2- thienylmethylene) -2,5-piperazinedione.
5388 (3Z, 6Z) -6-Benzylidene-3- (5- (2- (2- dimethylaminoethoxy) ethoxy) -2-thienylmethylene) -2,5- piperazinedione.
5389 (3Z,6Z) -6-Benzylidene-3- (5- (6-dimethylaminohexyloxy) - 2-thienylmethylene) -2,5-piperazinedione.
5299 (3Z,6Z) -6-Benzylidene-3- (5- (2- dimethylaminoethyl)methylamino-2-thienylmethylene) -2,5- piperazinedione.
5075 (3Z,6Z)-3- (2,5-Dichloro-3-thenylidene) -6-benzylidene-
2,5-piperazinedione.
5371 N- (4- (l,2,3,4-Tetrahydro-2-isoquinolyl)butyl) -4- ( (3Z, 6Z) -6-benzylidene-2,5-dioxo-3- piperazinylidene)methylbenzamide.
5391 N- (2- (l,2,3,4-Tetrahydro-2-isoquinolyl)ethyl) -4-
( (3Z, 6Z) -6-benzylidene-2,5-dioxo-3- piperazinylidene)methylbenzamide. 5394 N- (3- (1,2,3,4-Tetrahydro-2-isoquinolyl)propyl) -4-
( (3Z, 6Z) -6-benzylidene-2,5-dioxo-3- piperazinylidene)methylbenzamide.
5393 N- (4- (2- (1, 2, 3,4-Tetrahydro-2- isoquinolyl)ethyl)phenyl-4- ( (3Z,6Z) -6-benzylidene-2,5- dioxo-3-piperazinylidene)methylbenzamide. 5402 N- (4- (2- (l,2,3,4-Tetrahydro-2- isoquinolyl)ethyl)phenyl) -4- ( (3Z,6Z) -2,5-dioxo-6- (4- nitrobenzylidene) -3-piperazinylidene)methylbenzamide.
Compounds of formula A, may be prepared by a process which comprises either (i) condensing compound of formula
wherein R2 is as defined above and is optionally protected, with a compound of formula (II) :
Ri—CHO (II)
wherein Rj_ is as defined above and is optionally protected, in the presence of a base in an organic solvent; or (ii) condensing a compound of formula (I') :
wherein Rx is as defined above and is optionally protected, with a compound of formula (III) :
R—CHO (III)
wherein R2 is as defined above and is optionally protected, in the presence of a base in an organic solvent; and, in either case (i) or (ii) , if required, removing optionally present protecting groups and/or, if desired, converting one compound of formula A into another compound of formula A, and/or, if desired, converting a compound of formula A into a pharmaceutically acceptable salt or ester thereof, and/or, if desired, converting a salt or ester into a free compound, and/or, if desired, separating a mixture of isomers of compounds of formula A into the single isomers. A compound of formula A produced directly by the condensation reaction between (I) and (II) or (I') and (III) may be modified, if desired, by converting R-. into a different Rj, group. These optional conversions may be carried out by methods known in themselves. For example, a compound of formula A in which R1 comprises an ester group may be converted to a compound of formula A wherein the corresponding substituent is a free -COOH or OH group, by acid or alkaline hydrolysis at a suitable temperature, for example from ambient temperature to lOOoc. A compound of formula A in which either or both of R-. and R2 includes an -OH group may be converted into a compound of formula A wherein the corresponding substituent is esterified, for example by treating with a suitable carboxylic acid in the presence of an appropriate coupling agent, acid anhydride or acid chloride in an inert solvent. A compound of formula A in which either or both of R1
and R2 includes a -C02H group may be converted into a compound of formula A wherein the corresponding substituent is esterified, for example by treating the carboxylic acid with a suitable C-^-Cg alkyl alcohol in the presence of 1,3- dicyclohexylcarbodiimide in an inert solvent. A compound of formula A in which either or both of Rx and R2 includes a free -C02H group may be converted into a compound of formula A in which the corresponding substituent is a group -C0N(RX1R12) , wherein RX1 and R12 are as defined above, for example by treatment with ammonia or an amine in the presence of 1,3-dicyclohexylcarbodiimide in an inert solvent.
A compound of formula A in which either or both of R-, and R2 includes a free -C02H group may be converted into a compound of formula A wherein the corresponding substituent is a -CH2OH group by reduction, for example using borane in a suitable solvent such as tetrahydrofuran.
A compound of formula A in which either or both of R1 and R2 is a nitro group may be converted into a compound of formula A in which the corresponding substituent is an amino group by reduction under standard conditions, for example by catalytic hydrogenation.
Protecting groups for substituents on R and/or R2 in any of the compounds of formulae (I), (I'), (II) and (III) are optionally introduced prior to step (i) or step (ii) when either or both Rx and R2 include one or more groups which are sensitive to the condensation reaction conditions or incompatible with the condensation reaction, for example a -C00H, -CH20H or amino group. The protecting groups are then removed at the end of the process. Any conventional protecting group suitable for the group R-, and/or R2 in question may be employed, and may be introduced and subsequently removed by well-known standard methods. The condensation reaction between compounds (I) and (II) or (I') and (III) is suitably performed in the presence of a base which is potassium t-butoxide, sodium hydride, potassium carbonate, sodium carbonate, caesium carbonate, sodium acetate, potassium fluoride on alumina, or triethylamine in a solvent such as dimethylformamide, potassium t-butoxide in t-butanol, or a mixture of t- butanol and dimethylformamide (DMF) . The reaction is typically performed at a temperature from 0°c to the reflux temperature of the solvent. The compounds of formula (I) may be prepared by a process comprising reacting l,4-diacetyl-2,5- piperazinedione with a compound of formula (III) as defined above, in the presence of a base in an organic solvent. Similarly, the compounds of formula (I') may be prepared by a process which comprises reacting l,4-diacetyl-2,5- piperazinedione with a compound of formula (II) as defined above, in the presence of a base in an organic solvent.
If necessary, the resulting compound of formula (I) or (I') can be separated from other reaction products by chromatography.
The reaction of 1,4-diacetyl-2, 5-piperazinedione with the compound of formula (III) or (II) is suitably performed under the same conditions as described above for the condensation between compounds (I) and (II), or (I') and (III) .
The substituted aldehydes of formulae (II) and (III) are known compounds or can be prepared from readily available starting materials by conventional methods. The 1,4-diacetyl-2, 5-piperazinedione used as a starting material in the preparation of compounds of formula (I) may be prepared by treating 2, 5-piperazinedione (glycine anhydride) with an acetylating agent. The acetylation may be performed using any conventional acetylating agent, for example acetic anhydride under reflux or, alternatively, acetic anhydride at a temperature below reflux in the presence of 4-dimethylaminopyridine.
Compounds of formula (I) may also be prepared by the microwave irradiation of a mixture comprising 1,4-diacetyl- 2, 5-piperazinedione, a compound of formula (III) and potassium fluoride on alumina (as base) in the absence of solvent.
Compounds of formula (I) may alternatively be prepared directly from 2, 5-piperazinedione (glycine anhydride) by a process which comprises treating the 2,5-piperazinedione with a mixture comprising a compound of formula (III) , sodium acetate and acetic anhydride at an elevated temperature, for example under reflux. Compounds of formula (I') may be prepared by analogous processes, replacing compound (III) in each case by a compound of formula (II) .
Compounds of formula A may also be prepared by a process comprising the microwave irradiation of (i) a mixture comprising a compound of formula (I) as defined above, a compound of formula (II) and potassium fluoride on alumina, or (ii) a mixture comprising a compound of formula (I') a compound of formula (III) and potassium fluoride on alumina, or (iii) a mixture comprising 1,4-diacetyl-2, 5- piperazinedione, a compound of formula (II) , a compound of formula (III) and potassium fluoride on alumina. The irradiation is performed in the absence of a solvent. Compounds of formula (A) may also be obtained directly by a process which comprises condensing together 1,4- diacetyl-2, 5-piperazinedione, a compound of formula (II) and a compound of formula (III) in the presence of a base in an organic solvent. Suitable bases, solvents and reaction conditions are as described above for the condensation reaction between, for example, compounds (I) and (II) .
An alternative direct process for the preparation of compounds of formula (A) comprises condensing together 2,5- piperazinedione, a compound of formula (II) and a compound of formula (III) in the presence of sodium acetate and acetic anhydride at elevated temperature, for example under reflux.
An alternative process for the preparation of compounds of formula (I) comprises treating a compound of formula (V) : wherein R6 to R10 are as defined above, X is a halogen and R' is a CJ-CJ alkyl group, with ammonia followed by acetic anhydride.
Compounds of formula (I') may be prepared by an analogous process which comprises treating a compound of formula (V ) :
wherein Rx to Rs, X and R' are as defined above, with ammonia followed by acetic anhydride.
X in formula (V) or (V) is typically iodine. R' is, for example, a Cx-C4 alkyl group such as a methyl, ethyl, propyl, i-propyl, butyl, sec-butyl or tert-butyl group.
A review of synthetic approaches to unsaturated 3- monosubstituted and 3, 6-disubstituted-2,5-piperazinediones is provided in Heterocycles, 1983, 2J), 1407 (C.Shin) .
Compounds of formula (A) may be optionally washed after any of the above preparative procedures with one or more of the following: water, ethanol, ethyl acetate and diethyl ether.
Where appropriate compounds of formula (A) may be optionally recrystallised from a suitable solvent such as methanol or acetic acid.
Compounds of formula (A) may be converted into pharmaceutically acceptable salts, and salts may be converted into the free compound, by conventional methods. Suitable salts include salts with pharmaceutically acceptable, inorganic or organic, acids or bases. Examples of inorganic bases include ammonia and carbonates, hydroxides and hydrogen carbonates of group I and group II metals such as sodium, potassium, magnesium and calcium. Examples of organic bases include aliphatic and aromatic amines such as methylamine, triethylamine, benzylamine, dibenzylamine or a- or β-phenylethylamine, and heterocyclic bases such as piperidine, 1-methylpiperidine and morpholine. Examples of inorganic acids include hydrochloric acid, sulphuric acid and orthophosphoric acid. Examples of organic acids include p-toluenesulphonic acid, methansulphonic acid, mucic acid and succinic acid.
Compounds of formula (A) may also be converted into pharmaceutically acceptable esters. Suitable esters include branched or unbranched, saturated or unsaturated d-Cg alkyl esters, for example methyl, ethyl and vinyl esters.
The diketopiperazines of formula (A) , both novel and known and their pharmaceutically acceptable salts and esters (referred to hereinafter as the "present compounds") have utility as inhibitors of PAI. Elevated levels of PAI- 1, by reducing the net endogenous fibrinolytic capacity, can contribute to the pathogenesis of various thrombotic disorders including myocardial infarction, deep vein thrombosis and disseminated intravascular coagulation. The present compounds therefore can act as inhibitors of the tPA/PAI-1 interaction. The present compounds can be used in the treatment of haemostatic disorders. A human or animal, e.g. a mammal, can therefore be treated by a method comprising administration of a therapeutically effective amount of a diketopiperazine of formula (A) or a pharmaceutically or veterinarily acceptable salt thereof. Tissue plasminogen activator (tPA) is used as a fibrinolytic agent in the treatment of thrombotic disorders. The efficacy of the tPA in this role may be enhanced if it is administered together with a PAI inhibitor. A human or animal, e.g. a mammal, can therefore be treated by a method comprising the combined administration of a therapeutically effective amount of tPA and a therapeutically effective amount of any one of the present compounds. The present invention also provides products containing a diketopiperazine of formula (A) or a pharmaceutically acceptable salt or ester thereof and tPA as a combined preparation for simultaneous, separate or sequential use in the treatment of thrombotic disorders, for example where there is inappropriate PAI activity. In such products the present compound is formulated for oral or parenteral (intravenous, intramuscular or subcutaneous) administration and the tPA is formulated for intravenous administration. As one example, during acute myocardial infarction (MI) one of the present compounds may be administered to a patient together with tPA to enhance the efficacy of the tPA treatment. As a further example, early re-occlusion following treatment of a patient with tPA may be prevented by the post-MI administration of one of the present compounds.
The compounds of formula (A) have been tested in a PAI functional assay. In this assay, a compound is incubated with PAI-1 prior to addition to the tPA assay system.
Inhibition of PAI-1 results in the production of plasmin from plasminogen. In turn, plasmin cleaves the chromogenic substrate S2251 (Kabi Vitrum) producing pNA (p- nitroaniline) which is detected spectrophotometrically at 405 nm (K.Nilsson et al, Fibrinolysis (1987) .1, 163-168) . The results of the assay are reported below.
The present compounds can be administered in a variety of dosage forms, for example orally such as in the form of tablets, capsules, sugar- or film-coated tablets, liquid solutions or suspensions or parenterally, for example intramuscularly, intravenously or subcutaneously. The present compounds may therefore be given by injection or infusion.
The dosage depends on a variety of factors including the age, weight and condition of the patient and the route of administration. Typically, however, the dosage adopted for each route of administration when a compound of the invention is administered alone to adult humans is 0.001 to 10 mg/kg, most commonly in the range of 0.01 to 5 mg/kg, body weight. Such a dosage may be given, for example, from 1 to 5 times daily by bolus infusion, infusion over several hours and/or repeated administration. When one of the present compounds is administered in combination with tPA to adult humans, the dosage adopted for each route of administration is typically from 0.001 to 10 mg, more typically 0.01 to 5 mg per kg body weight for a compound of the invention and from 5 to 500mg administered intravenously for the tPA. A suitable dosage regimen for the tPA is 100 mg given intravenously over 3 hours as follows: 10% of the total dose as an i.v. bolus over 1-2 minutes, 50% of the total dose as an infusion over 1 hour, 40% of the total dose as an infusion over the subsequent 2 hours.
A diketopiperazine of formula (A) or a pharmaceutically acceptable salt or ester thereof is formulated for use as a pharmaceutical or veterinary composition also comprising a pharmaceutically or veterinarily acceptable carrier or diluent. The compositions are typically prepared following conventional methods and are administered in a pharmaceutically or veterinarily suitable form. An agent for use as an inhibitor of PAI comprising any one of the present compounds is therefore provided.
For example, the solid oral forms may contain, together with the active compound, diluents such as lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants such as silica, talc, stearic acid, magnesium or calcium stearate and/or polyethylene glycols; binding agents such as starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose, or polyvinyl pyrrolidone; disintegrating agents such as starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs, sweeteners; wetting agents such as lecithin, polysorbates, lauryl sulphates. Such preparations may be manufactured in known manners, for example by means of mixing, granulating, tabletting, sugar coating, or film-coating processes.
Liquid dispersions for oral administration may be syrups, emulsions and suspensions. The syrups may contain as carrier, for example, saccharose or saccharose with glycerol and/or mannitol and/or sorbitol. In particular, a syrup for diabetic patients can contain as carriers only products, for example sorbitol, which do not metabolise to glucose or which only metabolise a very small amount to glucose. The suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose or polyvinyl alcohol.
Suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier such as sterile water, olive oil, ethyl oleate, glycols such as propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride. Some of the present compounds are insoluble - 26 - in water. A compound may be encapsulated within liposomes.
TESTING OF THE PRESENT COMPOUNDS AS PAI INHIBITORS
Compounds of formula (A) were tested in a PAI chromogenic substrate assay. In the assay (K.Nilsson, Fibrinolysis (1987) JL, 163-168) each compound was incubated with PAI-1 prior to addition to the tPA assay system. Inhibition of PAI-1 by the compound of formula (A) resulted in the production of plasmin from plasminogen. In turn, the plasmin cleaved the chromogenic substrate S2251 (Kabi- Vitrum) producing pNA (jD-nitroaniline) which was detected spectrophotometrically at 405 nm.
The degrees of inhibition observed in the chromogenic substrate assay at various concentrations, and/or IC50 values, of compounds of formula (A) are presented in Table 1. IC50 values for some compounds, not shown in Table 1, are listed in Table 2 which follows Table 1.
TABLE 1; INHIBITION OF PAI-1 IN THE S2251 CHROMOGENIC SUBSTRATE ASSAY
TABLE 2
Reference Example 1; Preparation of (3Z) -l-acetyl-3- benzylidene-2.5-piperazinedione
1,4-Diacetyl-2, 5-piperazinedione (25.Og, 126 mmol), which is compound (8) mentioned in Reference Example 3, was heated at 120-130oC in DMF (200 ml) with triethylamine
(17.6 ml, 126 mmol) and benzaldehyde (13.0 ml, 126 mmol) . After 4 h the mixture was cooled to room temperature and poured into EtOAc (1000 ml) , and washed three times with brine. Any solid formed at this stage was filtered off. The filtrate was dried (MgS04) and the solvent removed in vacuo. The residue was recrystallised from EtOAc:Hexane to give 11.78 g (38%) of the title compound as a yellow solid. -K NMR (CDC13 400 MHz) δ=2.69 (3H, s) 4.54 (2H, s) 7.20 (1H, s) 7.40 (3H, m) , 7.48 (2H, m) , 7.93 (1H, br.s)
MS(DCI,NH3) : 262 (MNH4\ 20%), 245 (MH*, 53%), 220 (52%) , 204 (100%) , 203 (100%)
Alternatively (3Z) -l-acetyl-3-benzylidene-2, 5- piperazinedione can be produced as follows:
(18) Compound 16 is treated with ammonia and subsequently with acetic anhydride to yield the title compound.
Reference Example 2: Preparation of (3Z) -l-acetyl-3- (4- acetamidobenzylidene) -2,5- piperazinedione
1,4-Diacetyl-2, 5-piperazinedione (10.Og, 50 mmol), prepared by the published procedure mentioned in Example 3, was stirred in DMF (40 ml) with 4-acetamidobenzaldehyde (8.24 g, 50 mmol) and triethylamine (7 ml, 50 mmol) and heated to 120oC. After 21. h the mixture was cooled to room temperature, diluted with EtOAc (100 ml) and stirred overnight. The solid formed was collected, washed with EtOAc and dried to give 8.46 g (56%) of a yellow solid.
XH NMR (CDC13+TFA, 400 MHz) δ=2.32 (3H, s) 2.72 (3H, s) 4.68 (2H, s) 7.36 (IH, s) 7.45 (2H, d, J=8Hz) 7.60 (2H, d, J=8Hz)
Reference Example 3 : Preparation of 1,4-Diacetyl-2,5- piperazinedione
(7) (8) 1,4-Diacetyl-2, 5-piperazine dione (8) was prepared by the published procedure (S.M. Marcuccio and J.A. Elix, Aust. J. Chem.. 1984, 3_7, 1791) .
Reference Example 4: (3Z)-l-Acetyl-3-(4- methoxybenzylidene) -2,5- pjperazinedione
(3Z) -l-Acetyl-3- (4-methoxybenzylidene) -2,5- piperazinedione (9) was prepared by the published procedure (T. Yokoi, L-M. Yang, T. Yokoi, R-Y. Wu, and K-H. Lee, J. Antibiot. , 1988, 41, 494) .
Reference Example 5: Preparation of (3Z) -l-acetyl-3- (2,6- dichlorobenzylidene) -2,5- piperazinedione l,4-Diacetyl-2, 5-piperazinedione prepared by the published procedure mentioned in Reference Example 3, was stirred in DMF with 2, 6-dichlorobenzaldehyde and triethylamine and heated to 120-130°C for l-3h. The title compound was obtained with a yield of 40%. Reference Example 6: Preparation of (3Z) -l-acetyl-3- (4-
!!_=. dimethylamino)propoxybenzylidene) -
2,5-piperazinedione 1,4-Diacetyl-2, 5-piperazinedione, prepared by the published procedure mentioned in Reference Example 3, was stirred in DMF with 4- (3-dimethylamino)propoxybenzaldehyde and triethylamine and heated to 120-130°C for 2-4h to give the title compound. By the same method, using 4- (2- dimethylamino)ethoxybenzaldehyde in place of the above- mentioned aldehyde, (3Z) -l-acetyl-3- (4- (2- dimethylamino) ethoxybenzylidene) -2, 5-piperazinedione was prepared.
Reference Example 7; (3Z.6Z) -3- (4-Hvdroxybenzylidene) -6-
(4-methoxybenzylidene) -2,5- piperazinedione (3Z, 6Z) -3- (4-Acetoxybenzylidene) -6- (4- methoxybenzylidene) -2,5-piperazinedione was treated with aqueous sodium hydroxide in THF at room temperature for 8 hrs to give the title compound (1519) in 30% yield.
Example 1; Preparation of 1470 3 (Z) -1-Acetyl-3-benzylidene-2, 5-piperazinedione (one equivalent) , which is compound 18 prepared according to Reference Example 1, was treated with 1-tert- butoxycarbonylpyrrole-2-carboxaldehyde in the presence of Cs2C03 (1-1.1 equivalents) in DMF at 80-lOOoC for 1-6 hours. The title compound was obtained in 24% yield.
The crude product was optionally, washed with water, methanol, ethyl acetate or diethylether and optionally recrystallised from methanol as appropriate.
By the same method, but replacing 1-tert- butoxycarbonylpyrrole-2-carboxaldehyde by the appropriately substituted aldehyde or benzaldehyde, the following compounds were prepared:
Example 2; Preparation of 1474
3 (Z) -1-Acetyl-3- (4-methoxybenzylidene) -2,5- piperazinedione prepared according to Reference Example 4, was treated with 2-thiophenecarboxaldehyde in the presence of Cs2C03 (1-1.1 equivalents) in DMF at 80-100oC for 1-6 hours. The title compound was obtained in 76% yield.
By the same method, but replacing 2- thiophenecarboxaldehyde by the appropriately substituted aldehyde, the following compounds were prepared:
The crude product was optionally washed with water, methanol, ethyl acetate and diethylether and optionally recrystallised from acetic acid or methanol as appropriate.
Example 3; Preparation of 1884
3 (Z) -1-Acetyl-3-benzylidene-2,5-piperazinedione (1 equivalent) , prepared according to Reference Example 1, was treated with cyclohexanecarboxaldehyde (4 equivalents) in the presence of 0.5M potassium tert-butoxide in tertiary butanol (2 equivalents) in DMF at O-lOOoC for 2 hours. The title compound was obtained with a yield of 58%. Purification was effected by recrystallisation from acetic acid.
1672 was prepared as above but replacing the 3 (Z) -1- acetyl-3-benzylidene-2, 5-piperazinedione with 3 (Z) -1- acetyl-3- (4-acetamidobenzylidene) -2,5-piperazinedione. The reaction was maintained for 18 hours. A low yield was obtained.
Example 4; Preparation of 1676 l-Acetyl-3- (4-acetamidobenzylidene) -2,5- piperazinedione (one equivalent) , prepared according to Reference Example 2, was treated with cinnamaldehyde in the presence of Cs2C03 (1-1.1 equivalents) in DMF at 80-100oc for 1-6 hours. The title compound was obtained in 46% yield.
Example 5; Preparation of 1618
l,4-Diacetyl-2, 5-piperazinedione, prepared by the published procedure mentioned in Reference Example 3, was stirred in DMF with 2-thiophenecarboxaldehyde (1 equivalent) and triethylamine (1 equivalent) at 120oC for 2-4h. (3Z) -l-Acetyl-3- (2-thenylidene) -2,5-piperazinedione was obtained with a yield of 36%.
(3Z) -l-Acetyl-3- (2-thenylidene) -2,5-piperazinedione (1 equivalent) was stirred in DMF with 3-1-tert- butoxycarbonylindole-3-carboxyaldehye (1 equivalent) in the presence of Cs2C03 (1-1.1 equivalents) at 80-lOOoC for 2- 3h. The title compound was obtained with a yield of 14%. Example 6; Preparation of 1542
3 (Z) -l-Acetyl-3- (2, 6-dichlorobenzylidene) -2,5- piperazinedione (1 equivalent) , prepared according to Reference Example 5 was treated with 3-furaldehyde (1 equivalent) in the presence of Cs2C03 (1-1.1 equivalents) in DMF at 80-lOOoC for 2-5 hours. The title compound was obtained in 46% yield.
By the same method, but replacing 3-furaldehyde by the appropriately substituted aldehyde, 1560 was obtained with a yield of 39%.
Example 7; Preparation of 1982
3 (Z) -l-Acetyl-3-benzylidene-2, 5-piperazinedione (1 equivalent) , as prepared in Reference Example 1, was treated with 4- (N- (3-dimethylaminoethyl) -N- methyl)aminomethylbenzaldehyde in the presence of Cs2C03 (1-1.1 equivalents) in DMF at 80-lOOoC for l-6h to give (3Z,6Z) -3-Benzylidene-6- (4- (N-dimethylaminoethyl) -N- methyl) aminomethylbenzylidene) -2, 5-piperazinedione in a yield of 50%.
Compound 1982, the hydrochloride salt of (3Z,6Z)-3- Benzylidene-6- (4- (N- (3-dimethylaminoethyl) -N- methyl) aminomethylbenzylidene) -2,5-piperazinedione, was prepared by bubbling HCl gas through a solution of the corresponding free base in THF, followed by evaporation to dryness. The yield was 45%. Example 8; Preparation of 1976
3 (Z) -l-Acetyl-3- (4- (3- dimethylamino)propoxybenzylidene) -2, 5-piperazinedione (1 equivalent) , prepared according to Reference Example 6 was treated with 3- (imidazol-l-yl)benzaldehyde (1 equivalent) in the presence of Cs2C03 (1-1.1 equivalent) in DMF at 80- 90°C for 2-4 hours. The title compound was obtained in 52% yield.
Example 9: Preparation of 1886
1519 (1 equivalent) , prepared in Reference Example 7, was treated in DMF with sodium hydride (1 equivalent) and N-phthaloylglycyl chloride (1 equivalent) in DMF at room temperature for 4h. The title compound was obtained with a yield of 30%.
Example 10: Preparation of 5026
(3Z) -l-acetyl-3- (4- (3-dimethylamino)propoxy- benzylidene) -2,5-piperazinedione, prepared as in Reference Example 6, was treated with compound 10.1 in dimethylformamide (DMF) in the presence of Cs2C03 at a temperature of 80°C-90°C for 2-4 hours. Compound 5026 was obtained in 95% yield.
By an analogous process, using the appropriately substituted benzaldehyde in place of compound 10.1, the following compounds were prepared:
Example 11; Preparation of 5027
5027 (3Z) -l-acetyl-3- (4- (3-dimethylamino)propoxybenzylidene) - 2, 5-piperazinedione, prepared as in Reference Example 6, was treated with compound 11.1 in DMF in the presence of Cs2C03 at 80°C-90°C for 2-4 hours. Compound 5027 was produced in 33% yield.
By the same method, but replacing 11.1 by the appropriately substituted aldehyde, the following compounds were prepared:
Example 12 : Preparation of 5023
5023 Compound 12.1 was treated with 4- (3- dimethylamino)propoxybenzaldehyde in DMF in the presence of Cs2C03 at a temperature of 80°C-90°C for 2-4 hours. Compound 5023 was obtained in 36% yield..
Example 13 ; Preparation of 5062
5062 (3Z) -l-acetyl-3- (4- (2-dimethylamino) ethoxybenzylidene) -2,5- piperazinedione, prepared as in Reference Example 6, was treated with compound 13.1 in DMF in the presence of Cs2C03 at a temperature of 80°C-90°C for 2-4 hours. Compound 5062 was obtained in 12% yield. By the same method, but using the appropriately substituted aldehyde in place of compound 13.1, the following compounds were prepared:
Example 14: Preparation of compounds of formula (I)
14.1 14.2
Compound (I)
The 2, 5-piperazinedione derivative 14.1 was treated with the aldehyde 14.2, the groups Ar and Subst. being as specified below, in DMF in the presence of Cs2C03 at 80°C- 90°C for 2-4 hours. The compounds of formula (I) listed below were prepared:
Example 15 : Preparation of compounds of formula (I)
15.1 15.2
Compound (I) The 2, 5-piperazinedione derivative 15.1 was treated with the aldehyde 15.2 in which R20 and R21 are both H or are both OMe, the substituent Ar and linking group A being as specified below, in DMF in the presence of Cs2C03 at 80°C to 90°C for 2-4 hours. The compounds of formula (I) listed below were prepared. In 5391, 5394 and 5371 R20 and R21 are both H. In 5393 and 5402 R20 and R21 are OMe.
Example 16; Preparation of compounds of formula (I)
(3Z) -l-acetyl-3-benzylidene-2, 5-dione prepared as in Reference Example 1 (compound 18) , was treated with the aldehyde 16.1 in which substituent Y was as indicated below, in DMF in the presence of Cs2C03 at 80°C-90°C for 2-4 hours. The compounds of formula (I) listed below were prepared:
By the same method, but using 2, 5-dichlorothiophene- 4-carboxaldehyde in place of compound 16.1, 5075 was prepared in 31% yield.
Example 17; Preparation of salts
1. Hydrochloride salts of the following compounds of formula (I) were prepared by bubbling HC1 gas through a solution of the corresponding free base in tetrahydrofuran (THF) at room temperature. The salt was recovered in the yield indicated.
2. Hydrochloride salts of the following compounds of formula (I) were prepared by bubbling HCl gas through a solution of the corresponding free base in hot DMF. The salt was recovered in the yield indicated.
3. Hydrochloride salts of the following compounds of formula (I) were prepared by treating the free base with 2M HCl:
4. 5043.HCl, the hydrochloride salt of 5043, was prepared by bubbling HCl gas through a solution of 5043 in MeOH. 5057.HCl, the salt of 5057, was prepared by bubbling HCl gas through a solution of 5057 in THF following by recrystallisation from MeOH.
Example 18: PHARMACEUTICAL COMPOSITION
Tablets, each weighing 0.15 g and containing 25 mg of a compound of the invention can be manufactured as follows: Composition for 10,000 tablets compound of the invention (250 g) lactose (800 g) corn starch (415 g) talc powder (30 g) magnesium stearate (5 g)
The compound of the invention, lactose and half of the corn starch are mixed. The mixture is then forced through a sieve 0.5 mm mesh size. Corn starch (10 g) is suspended in warm water (90 ml) . The resulting paste is used to granulate the powder. The granulate is dried and broken up into small fragments on a sieve of 1.4 mm mesh size. The remaining quantity of starch, talc and magnesium stearate is added, carefully mixed and processed into tablets. Example 19: Characterisation of compounds of formula
A
The compounds prepared in the preceding Examples, were characterised by mass spectroscopic, microanalytical, proton nuclear magnetic resonance and, in some cases, infra-red techniques. The results are set out in the Tables which follow:
I Ul
LΠ t
LΠ
Λ 9 n
LΠ * 3 — t s
in
3
I
Ul
LΠ oo
>
O n
n
L v O — n
Λ O Λ
n σ. o
3
Λ
Λ
0\ 3 to — >
cr.
Λ J Λ
n cr.
*3 — >
3
I
( l σ.
3
>
cr.
n
σ.
3 -
(Tι VO
o
m
M CΛ
^1 to
~
J .
•0
3
>
I
-O σ. - o

Claims

1. A piperazine of general formula (A):
wherein one or both of R1 and R2, which may be the same or different, is:
(I) X, or a phenyl group which is substituted by X, C(O)X, OC(O)CH2X, OCH2CH2X, CH2X, CONH(CH2)nX,
O(CH2)nCH(OH) (CH2)nX or
or which is fused to a group X;
(II) a phenyl group substituted by CH2NR12R13,
OC(O) (CH2)nZ, CH(OR12) (OR13) , (CH2)nNR14C(O) (CH2)mNR12R13,
-CH2NR12-(CH2)nNR15R16, O(CH2)nCH(OH) (CH2)nN(R12R13) ;
(III) a group CH=C(W)V; or
(IV) a cyclohexyl group;
and where appropriate, the other of R1 and R2 is a phenyl group optionally substituted by one or more groups
independently selected from halogen, nitro, methoxy,
NHC(O)R12, CO2H, O(CH2)nN(R12R13) , CH2Y(CH2)nN(R12R13) ,
C1-C4 alkyl and (CH2)nC(O)OR12;
X is a naphthyl group or a five- or six-membered saturated or unsaturated heterocyclic group containing one or more heteroatoms, which heteroatoms may be the same or different and are independently selected from O, N and S; the heteroatom(s) when nitrogen being optionally substituted by hydrogen, methyl, oxygen, tertiary-butyloxycarbonyl,
-(CH2)nCH2OH or SO2Me; the heterocyclic ring being
optionally substituted by halogen, Me, MeS, phenyl,
O ( CH2 ) nNR12R13 , -N (R12 ) ( CH2 ) nN (R12R13 ) , - ( CH2 ) nN (R12R13 ) or
-O(CH2)nO(CH2)nN(R12R13), or the heterocyclic ring optionally containing one or more carbonyl groups and being optionally fused to a benzene ring, which benzene ring is optionally substituted by 1 or 2 C1-C6 alkoxy groups;
Y is O or S;
Z is a C3-C6 cycloalkyl group;
R12, R13 and R14, which may be the same or different, are hydrogen or C1-C6 alkyl;
R15 and R16, which may be the same or different, are
hydrogen or C1-C6 alkyl, or R15 and R16 form, together with the atom to which they are attached, a 5- or 6-membered heterocyclic group;
W is hydrogen or a phenyl group;
V is a phenyl group optionally substituted by one or more groups independently selected from nitro, alkoxy and
O ( CH2 ) nNR12R13 ;
m and n are each, independently, 0 or an integer having the value 1, 2, 3 or 4;
O(CH2)nNR12R13 or containing one or more carbonyl groups and being optionally fused to a benzene ring;
Z is a C3-C6 cycloalkyl group;
R12, R13 and R14, which may be the same or different, are hydrogen or C1-C4 alkyl;
W is hydrogen or a phenyl group;
V is a phenyl group optionally substituted by one or more groups independently selected from nitro, alkoxy and
O(CH2)nNR12R13; and
m and n are, independently, integers having the values 1,
2, 3 or 4;
or a pharmaceutically acceptable salt or ester thereof.
2 . A compound according to claim 1, wherein one or both of R1 and R2, which may be the same or different, is chosen from X and a phenyl group substituted by X, C(O)X, OC(O)CH2X, OCH2CH2X, CH2X or which is fused to a group X; X is a five- or six-membered heterocyclic ring containing one or two heteroatoms, which may be the same or different, independently selected from O, N and S, the heteroatoms (s) when nitrogen being optionally substituted by hydrogen, methyl, oxygen, tertiary-butyloxycarbonyl, or SO2Me, the heterocyclic ring being optionally substituted by hydrogen, methyl, phenyl, O(CH2)nN(R12R13) or optically containing one or more carbonyl groups and being optionally fused to a benzene ring; Y, R12, R13 and n are as defined in claim 1.
3. A compound according to claim 1 or 2, wherein R12 and R13, which may be the same or different, are
hydrogen or C1-C3 alkyl and n is an integer of value 1 or 2.
4. A compound according to claim 1, 2, or 3 wherein one of R1 and R2 is a phenyl group which is
substituted by X, C(X), OCO(O)CH2X, OCH2CH2X, CH2X or which is fused to a group X; wherein X is a five- or six-membered heterocyclic ring containing one or two heteroatoms which may be the same or different, independently selected from
O, N and S, the heteroatoms(s) when nitrogen being
optionally substituted by methyl, the heterocyclic ring being optionally fused to a benzene ring.
5. A compound according to claim 1, wherein one of R1 and R2 is a phenyl group substituted by CH2NR12R13,
OC(O)(CH2)nZ, CH(OR12)(OR13), (CH2)n NR14C(O)(CH2)mNR12R13;
wherein R12, R13 and R14, which may be the same or different, are independently selected from hydrogen or C1-C3 alkyl; Z is a C5 or C6 cycloalkyl group;
and m and n are, independently, integers having the values
1, 2 or 3.
6. A compound according to claim 1 or 5 , wherein
R12, R13 and R14, which may be the same or different, are independently selected from hydrogen and C1-C2 alkyl;
Z is a cyclopentyl group; and
m and n are, independently, integers having the values of 1 or 2.
7. A compound selected from
1926 (3Z,6Z)-3-Benzylidene-6-(4-imidazolyl)methylene-2,5-piperazinedione.
1930 (3Z,6Z)-3-Benzylidene-6-(4-(1-imidazolyl)benzylidene)-2,5-piperazinedione.
1929 (3Z,6Z)-3-Benzylidene-6-(4-(1-imidazolylmethyl)benzylidene)-2,5-piperazinedione.
1959 (3Z,6Z)-3,Benzylidene-6-(4-(2-dimethylaminoethoxy)-3- methoxybenzylidene)-2,5-piperazinedione hydrochloride.
1927 (3Z,6Z)-3-Benzylidene-6-(4-(5-methylimidazolyl))methylene-2,5-piperazinedione.
1921 (3Z,6Z)-3-Benzylidene-6-(4-dimethylaminocinnamylidene)-2,5-piperazinedione.
1976 (3Z,6Z)-3-(4-(3-Dimethylaminopropoxy)benzylidene)-6- (4-(1-imidazolyl)benzylidene-2,5-piperazinedione.
1910 (3Z,6Z)-3-Benzylidene-6-(4-(2-imidazolylethoxy)benzylidene)-2,5-piperazinedione.
1923 (3Z,6Z)-3-Benzylidene-6-(4-nitrocinnamylidene-2,5-piperazinedione.
1657 (3Z,6Z)-3-(4-Aminomethylbenzylidene)-6-(4-methoxybenzylidene)-2,5-piperazinedione.
1491 Methyl (3Z,6Z)-3-benzylidene-6-(4-methoxybenzylidene)-2-oxo-1,2,3,6-tetrahydro-5-pyrazonyloxyacetate.
1693 (3Z,6Z)-3-(l-methanesulfonyl-3-indolyl)methylene-6-(4-methoxybenzylidene)-2,5-piperazinedione.
1886 (3Z,6Z)-3-(4-Methoxybenzylidene)-6-(4-phthalimidoacetoxybenzylidene)-2,5-piperazinedione.
1922 (3Z,6Z)-3-Benzylidene-6-(γ-phenylcinnamylidene)-2,5-piperazinedione.
1618 (3Z,6Z)-3-(1-tert-butoxycarbonyl-3-indolyl)methylene- 6-(2-thenylidene)-2,5-piperazinedione.
1560 (3Z,6Z)-3-(2,6-Dichlorobenzylidene)-6-(1-tert-butoxycarbonyl-3-indolyl)methylene-2,5-piperazinedione.
1950 (3Z,6Z)-3-Benzylidene-6-(4-(2-dimethylaminoethoxy)-3-methoxycinnamylidene)-2,5-piperazinedione.
1975 (3Z,6Z)-3-(4-(3-Dimethylaminopropoxy)benzylidene)-6- (4-(1-imidazolylmethyl)benzylidene)-2,5-piperazinedione.
1983 (3Z,6Z)-3-Benzylidene-6-(4-N-methyl-N-(4-(N-methylpiperidinyl))aminomethylbenzylidene-2,5-piperazinedione.
1509 ((3Z,6Z)-3-Benzylidene-6-(3-indolylmethylene)-2,5-piperazinedione.
1542 (3Z,6Z)-3-(2,6-Dichlorobenzylidene)-6-(3-furylmethylene)-2,5-piperazinedione.
1545 (3Z,6Z)-3-(3-Indoxylmethylene)-6-(4-methoxybenzylidene)-2,5-piperazinedione.
1560 (3Z,6Z)-3-(2,6-Dichlorobenzylidene)-6-(3-(1-tertbutoxycarbonyl)indolyl)methylene-2,5-piperazinedione.
1507 (3Z,6Z)-3-(4-Methoxybenzylidene)-6-(2-(1-tertbutoxycarbonyl)pyrrolyl)methylene-2,5-piperazinedione. 1506 (3Z,6Z)-3-(4-Methoxybenzylidene)-6-(3-(1-tert-butoxyarbonyl)indolyl)methylene-2,5-piperazinedione.
1471 (3Z,6Z)-3-Benzylidene-6-(3-(1-tert-butoxycarbonyl)indolyl)methylene-2,5-piperazinedione.
1474 (3Z,6Z)-3-(4-Mehtoxybenzylide-ne)-6-(2-thienylmethylene)-2,5-piperazinedione.
1476 (3Z,6Z)-3-(4-Methoxybenzylidene)-6-(3-furylmethylene) 2,5-piperazinedione.
1672 (3Z,6Z)-3-(Acetamidobenzylidene)-6-cyclohexylmethylene-2,5-piperazinedione.
1676 (3Z,6Z)-3-(4-Acetamidobenzylidene)-6-cinnamylidene- 2,5-piperazinedione.
1891 (3Z,6Z)-3-Benzylidene-6-(diethoxymethylbenzylidene)- 2,5-piperazinedione. 1982 (3Z , 6Z) -3 -Benzylidene-6- (4 - (N-methyl-N- (2 -dimethylaminoethyl)aminomethylbenzylidene-2,5-piperazinedione hydrochloride.
1884 (3Z,6Z)-3-Benzylidene-6-cyclohexylmethylene-2,5-piperazinedione.
1845 (3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(3,4-methylenedioxybenzylidene)-2,5-piperazinedione.
1718 (3Z,6Z)-3-(2-Indolylmethylene)-6-(4-methoxybenzylidene)-2,5-piperazinedione.
1808 (3Z,6Z)-3-Benzylidene-6-(3,4-methylenedioxybenzylidene)-2,5-piperazinedione.
1809 (3Z,6Z)-3-(4-Methoxybenzylidene)-6-(3,4-methylenedioxybenzylidene)-2,5-piperazinedione.
1470 (3Z,6Z)-3-Benzylidene-6-(2-(1-tertbutoxycarbonyl)pyrrolyl)methylene-2,5-piperazinedione.
5023 (3Z,6Z)-3-(4-Dimethylaminomethylbenzylidene)-6-(4-(3-dimethylaminopropoxy)benzylidene-2,5-piperazinedione.
5026 (3Z,6Z)-3-(4-(3-Dimethylaminopropoxy)benzylidene)-6- (4-(1-imidazolyl)methylbenzylidene)-2,5-piperazinedione. 5030 (3Z,6Z)-3-(4-(3-Dimethylaminopropoxy)benzylidene)-6- (4-(1-imidazolyl)benzylidene.
5367 (2-(4-((3Z,6Z)-6-(4-(3- Dimethylaminopropoxy)benzylidene)-2,5-dioxo-3-piperazinylidene)methylbenzoyl)-1,2,3,4-tetrahydroisoquinoline.
5386 N-(2-(1,2,3,4-Tetrahydro-2-isoquinolyl)ethyl)-4- ((3Z,6Z)-6-(4-(3-dimethylaminopropoxy)benzylidene)-2,5-dioxo-3-piperazinylidene)methylbenzamide. 5397 N-(4-(1,2,3,4-Tetrahydro-2-isoquinolyl)butyl)-4- ((3Z,6Z)-6-(4-(3-dimethylaminopropoxy)benzylidene)-2,5-dioxo-3-piperazinylidene)methylbenzamide.
5027 (3Z,6Z)-6-(4-(3-Dimethylaminopropoxy)benzylidene-3- (4-pyridylmethylene)-2,5-piperazinedione.
5028 (3Z,6Z)-6-(4-(3-Dimethylaminopropoxy)benzylidene)-3- (3-pyridylmethylene)-2,5-piperazinedione.
5041 (3Z,6Z)-6-(4-(3-Dimethylaminopropoxy)benzylidene)-3-furfurylidene-2,5-piperazinedione.
5042 (3Z,6Z)-6-(4-(3-Dimethylaminopropoxy)benzylidene)-3- (3-Thenylidene)-2,5-piperazinedione.
5046 (3Z,6Z)-6-(4-(3-Dimethylaminopropoxy)benzylidene)-3- (2-Thenylidene)-2,5-piperazinedione.
5052 (3Z,6Z)-6-(4-(3-Dimethylaminopropoxy)benzylidene)-3- (3-Furylmethylene)-2,5-piperazinedione.
5188 (3Z,6Z)-6-(4-(3-Dimethylaminopropoxy)benzylidene)-3- (2-Naphthylmethylene)-2,5-piperazinedione.
5200 (3Z,6Z)-6-(4-(3-Dimethylaminopropoxy)benzylidene)-3- (1-Naphthylmethylene)-2,5-piperazinedione.
5032 (3Z,6Z)-6-Benzylidene-3-(4-(3-dimethylamino-2-hydroxypropoxy)benzylidene)-2,5-piperazinedione.
5040 (3Z,6Z)-6-Benzylidene-3-(4-(2-hydroxy-3-morpholinopropoxy)benzylidene)-2,5-piperazinedione.
5057 (3Z,6Z)-6-Benzylidene-3-(4-(2-hydroxy-3-(1-imidazolyl)propoxy)benzylidene)-2,5-piperazinedione.
5043 (3Z,6Z)-6-Benzylidene-3-(4-(2-hydroxy-3-(4-(2-hydroxyethyl)-1-piperazinyl)propoxy)benzylidene)-2,5-piperazinedione. 5062 (3Z,6Z)-6-(4-(2-Dimethylaminoethoxy)benzylidene)-3- (3-Furylmethylene)-2,5-piperazinedione.
5071 (3Z,6Z)-6-(4-(2-Dimethylaminoethoxy)benzylidene)-3- (3-thenylidene)-2,5-piperazinedione.
5072 (3Z,6Z)-6-(4-(2-Dimethylaminoethoxy)benzylidene)-3- (5-methylthio-2-thenylidene)-2,5-piperazinedione.
5054 (3Z,6Z)-6-Benzylidene-3-(4-(2-morpholinoethoxy)benzylidene)-2,5-piperazinedione.
5055 (3Z,6Z)-6-Benzylidene-3-(4-(2-(1-imidazolyl)ethoxy)benzylidene)2,5-piperazinedione.
5053 (3Z,6Z)-6-Benzylidene-3-(4-(2-(1-pyrrolidinyl)ethoxy)benzylidene)2,5-piperazinedione.
5069 (3Z,6Z)-6-(4-(2- Dimethylaminoethoxymethyl)benzylidene)-3-(3-thenylidene)-2,5-piperazinedione.
5077 (3Z,6Z)-6-(4-(2- Dimethylaminoethoxymethyl)benzylidene)-3-(3-furylmethylene)-2,5-piperazinedione.
5074 (3Z,6Z)-6-(4-Dimethylaminoacetamidomethyl
benzylidene)-3-(3-thenylidene)-2,5-piperazinedione.
5079 (3Z,6Z)-3-(2-Bromobenzylidene)-6-(4-dimethylaminoacetamidomethylbenzylidene)-2,5-piperazinedione.
5081 (3Z,6Z)-6-(4-Dimethylaminoacetamidomethylbenzylidene)-3-(3-furylmethylene)-2,5-piperazinedione.
5061 (3Z,6Z)-6-Benzylidene-3-(4-dimethylaminoacetamidomethylbenzylidene)-2,5- piperazinedione.
5073 (3Z,6Z)-6-(4-(2- Dimethylaminoethylthiomethyl)benzylidene)-3-(3-furylmethylene)-2,5-piperazinedione.
5078 (3Z,6Z)-6-(4-(2- Dimethylaminoethylthiomethyl)benzylidene)-3-(3-thenylidene)-2,5-piperazinedione.
1912 (3Z,6Z)-6-Benzylidene-3-(4-dimethylaminoacetamidoaminomethylbenzylidene)-2,5-piperazinedione.
5324 (3Z,6Z)-6-Benzylidene-3-(5-(2-dimethylaminoethoxy)-2-thienylmethylene)-2,5-piperazinedione.
5327 (3Z,6Z)-6-Benzylidene-3-(4-(2-dimethylaminoethoxy)-2-thienylmethylene)-2,5-piperazinedione.
5335 (3Z,6Z)-6-Benzylidene-3-(5-(2-dimethylaminoethyl)-2-thienylmethylene)-2,5-piperazinedione.
5388 (3Z,6Z)-6-Benzylidene-3-(5-(2-(2-dimethylaminoethoxy)ethoxy)-2-thienylmethylene)-2,5-piperazinedione.
5389 (3Z,6Z)-6-Benzylidene-3-(5-(6-dimethylaminohexyloxy)- 2-thienylmethylene)-2,5-piperazinedione.
5299 (3Z,6Z)-6-Benzylidene-3-(5-(2-dimethylaminoethyl)methylamino-2-thienylmethylene)-2,5-piperazinedione.
5075 (3Z,6Z)-3-(2,5-Dichloro-3-thenylidene)-6-benzylidene- 2,5-piperazinedione.
5371 N-(4-(1,2,3,4-Tetrahydro-2-isoquinolyl)butyl)-4- ((3Z,6Z)-6-benzylidene-2,5-dioxo-3- piperazinylidene)methylbenzamide.
5391 N-(2-(1,2,3,4-Tetrahydro-2-isoquinolyl)ethyl)-4- ((3Z,6Z)-6-benzylidene-2,5-dioxo-3-piperazinylidene)methylbenzamide.
5394 N-(3-(1,2,3,4-Tetrahydro-2-isoquinolyl)propoyl)-4- ((3Z,6Z)-6-benzylidene-2,5-dioxo-3-piperazinylidene)methylbenzamide.
5393 N-(4-(2-(1,2,3,4-Tetrahydro-2-isoquinolyl)ethyl)phenyl-4-((3Z,6Z)-6-benzylidene-2,5-dioxo-3-piperazinylidene)methylbenzamide.
5402 N-(4-(2-(1,2,3,4-Tetrahydro-2-isoquinolyl)ethyl)phenyl)-4-((3Z,6Z)-2,5-dioxo-6-(4-nitrobenzylidene)-3-piperazinylidene)methylbenzamide.
8. A pharmaceutical or veterinary composition comprising a pharmaceutically or veterinarily acceptable carrier or diluent and, as an active principle, a compound as defined in claim 1.
9. A process for preparing a compound of formula (A) as defined in claim 1, the process comprising:
(a) condensing a compound of formula (I):
wherein R2 are as defined in claim 1 and is optionally protected, with a compound of formula (II):
R1—CHO (II) wherein R2 is as defined in claim 1 and is optionally protected, in the presence of a base in an organic solvent; or
(b) condensing a compound of formula (I'):
wherein R1 is as defined in claim 1 and are optionally protected with a compound of formula (III):
R2—CHO ( III) wherein R2 is as defined in claim 1 and is optionally protected, in the presence of a base in an organic solvent; and
(c) if required, removing optionally present protecting groups, and/or, if desired, converting one compound of formula A into another compound of formula A, and/or, if desired, converting a compound of formula A into a pharmaceutically acceptable salt or ester thereof, and/or, if desired, converting a salt or ester into a free compound, and/or, if desired, separating a mixture of isomers into the single isomers.
10. Use of a diketopiperazine of formula (A):
wherein one or both of R1 and R2, which may be the same or different, is:
(I) X, or a phenyl group which is substituted by X, C(O)X, OC(O)CH2X, OCH2CH2X, CH2X, CONH(CH2)nX,
O(CH2)nCH(OH) (CH2)nX or
or which is fused to a group X;
(II) a phenyl group substituted by CH2NR12R13,
OC(O) (CH2)nZ, CH(OR12) (OR13) , (CH2)nNR14C(O) (CH2)mNR12R13 or O(CH2)nCH(OH) (CH2)nN(R12R13) ;
(III) a group CH=C(W)V; or
(IV) a cyclohexyl group;
and where appropriate, the other of R1 and R2 is a phenyl group optionally substituted by one or more groups
independently selected from halogen, nitro, methoxy,
NHC(O)R12, CO2H, O(CH2)nN(R12R13) and CH2Y(CH2)nN(R12R13);
R3 is C1-C4 alkyl or (CH2)nC(O)OR12;
X is a naphthyl group or a five- or six-membered saturated or unsaturated heterocyclic group containing one or more heteroatoms, which heteroatoms may be the same or different and are independently selected from O, N and S; the
heteroatom(s) when nitrogen being optionally substituted by hydrogen, methyl, oxygen, tertiary-butyloxycarbonyl,
-(CH2)nCH2OH or SO2Me; the heterocyclic ring being
optionally substituted by halogen, Me, MeS, phenyl,
O(CH2)nNR12R13, -N(R12)(CH2)nN(R12R13), -(CH2)nN(R12R13) or
-O(CH2)nO(CH2)nN(R12R13), or the heterocyclic ring optionally containing one or more carbonyl groups and being optionally fused to a benzene ring, which benzene ring is optionally substituted by 1 or 2 C1-C6 alkoxy groups;
V is O or S;
Z is a C3-C6 cycloalkyl group;
R12, R13 and R14, which may be the same or different, are hydrogen or C1-C6 alkyl;
W is hydrogen or a phenyl group;
V is a phenyl group optionally substituted by one or more groups independently selected from nitro, alkoxy and
O ( CH2 ) nNR12R13 ;
m and n are each, independently, O or an integer having the value 1, 2, 3 or 4;
O(CH2)nNR12R13 or containing one or more carbonyl groups and being optionally fused to a benzene ring;
Z is a C3-C6 cycloalkyl group;
R12, R13 and R14, which may be the same or different, are hydrogen or C1-C4 alkyl;
W is hydrogen or a phenyl group;
V is a phenyl group optionally substituted by one or more groups independently selected from nitro, alkoxy and
O ( CH2 ) nNR12R13 ;
m and n are, independently, integers having the values 1, 2, 3 or 4;
or a pharmaceutically acceptable salt or ester thereof; in the manufacture of a medicament for use as an inhibitor of plasminogen activator inhibitor.
EP95908314A 1994-02-14 1995-02-14 Pharmaceutical piperazine compounds Withdrawn EP0745070A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9402807A GB9402807D0 (en) 1994-02-14 1994-02-14 Pharmaceutical compounds
GB9402807 1994-02-14
PCT/GB1995/000302 WO1995021832A1 (en) 1994-02-14 1995-02-14 Pharmaceutical piperazine compounds

Publications (1)

Publication Number Publication Date
EP0745070A1 true EP0745070A1 (en) 1996-12-04

Family

ID=10750355

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95908314A Withdrawn EP0745070A1 (en) 1994-02-14 1995-02-14 Pharmaceutical piperazine compounds

Country Status (8)

Country Link
EP (1) EP0745070A1 (en)
JP (1) JPH09509157A (en)
AU (1) AU693159B2 (en)
CA (1) CA2182877A1 (en)
GB (2) GB9402807D0 (en)
IL (1) IL112624A0 (en)
WO (1) WO1995021832A1 (en)
ZA (1) ZA951180B (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112627A0 (en) * 1994-02-14 1995-05-26 Xenova Ltd Diketopiperazines, their preparation and pharmaceutical or veterinary compositions containing them
GB9426090D0 (en) * 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
PL336628A1 (en) 1997-05-03 2000-07-03 Smithkline Beecham Plc Derivatives of tetrahydroisoquinoline as modulators of d3 dopamine receptors
ES2433641T3 (en) 1997-06-09 2013-12-12 Hitachi, Ltd. Image decoding and image decoder procedure
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
KR20010085898A (en) 1998-10-08 2001-09-07 피터 기딩스 Tetrahydrobenzazepine Derivatives Useful as Modulators of Dopamine D3 Receptors (Antipsychotic Agents)
US6972289B1 (en) * 2000-01-18 2005-12-06 Nereus Pharmaceuticals, Inc. Cell division inhibitor and a production method thereof
NZ522680A (en) * 2000-05-09 2005-08-26 Adpharma Inc Piperazinedione compounds
ATE417614T1 (en) * 2000-05-09 2009-01-15 Angiorx Corp PIPERAZINDIONE COMPOUNDS
US7288545B2 (en) 2000-05-09 2007-10-30 Angiorx Corporation Piperazinedione compounds
GB2372740A (en) * 2001-01-17 2002-09-04 Xenova Ltd Diketopiperazines
TW591020B (en) * 2001-06-20 2004-06-11 Wyeth Corp 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
ATE374767T1 (en) * 2002-08-02 2007-10-15 Nereus Pharmaceuticals Inc DEHYDROPHENYLAHISTINES AND ANALOGUES THEREOF AND A METHOD FOR PRODUCING DEHYDROPHENYLAHISTINES AND ANALOGUES THEREOF
CA2553630A1 (en) * 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
CA2566094A1 (en) 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. Cinnamide compound
KR20070083781A (en) 2004-10-26 2007-08-24 에자이 알앤드디 매니지먼트 가부시키가이샤 Amorphous object of cinnamide compound
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
WO2008044729A1 (en) 2006-10-12 2008-04-17 Institute Of Medicinal Molecular Design. Inc. Carboxylic acid derivative
AU2007307599A1 (en) 2006-10-12 2008-04-17 Institute Of Medicinal Molecular Design. Inc. N-phenyloxamic acid derivatives
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US20080207900A1 (en) 2007-02-28 2008-08-28 Teiji Kimura Two cyclic oxomorphorin derivatives
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
MY150507A (en) 2007-08-31 2014-01-30 Eisai R&D Man Co Ltd Polycyclic compound
CN102872020A (en) 2007-10-23 2013-01-16 株式会社医药分子设计研究所 Inhibitor of pai-1 production
CA2720096A1 (en) 2008-04-11 2009-10-15 Institute Of Medicinal Molecular Design, Inc. Pai-1 inhibitor
US20110144336A1 (en) * 2008-08-13 2011-06-16 Basf Se Method for Preparation of Piperazindione Derivatives
US8993555B2 (en) * 2012-12-21 2015-03-31 Epizyme, Inc. PRMT5 inhibitors and uses thereof
CN105272968B (en) * 2014-06-10 2018-03-13 首都医科大学 The diketone of (3S, 6R) 3,6 disubstituted piperazine 2,5, it is prepared and application
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
WO2016034671A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors
EP3189041B1 (en) 2014-09-03 2021-04-28 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
MX2017011374A (en) 2015-03-06 2018-01-23 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation.
CN107530340B (en) 2015-03-06 2021-06-08 大连万春布林医药有限公司 Method for treating brain tumors
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
AU2017217426B2 (en) 2016-02-08 2022-12-01 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
CN109475524A (en) 2016-06-06 2019-03-15 万春药业公司 For reducing the composition and method of neutrophilic granulocytopenia
CN106565686B (en) * 2016-10-11 2019-03-01 深圳海王医药科技研究院有限公司 Antitubulin
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
CA3052190A1 (en) 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia
AU2018336171B2 (en) 2017-09-22 2023-01-05 Jubilant Epipad LLC Heterocyclic compounds as PAD inhibitors
PL3697785T3 (en) 2017-10-18 2023-08-07 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
AU2018362046B2 (en) 2017-11-06 2023-04-13 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
US11459338B2 (en) 2017-11-24 2022-10-04 Jubilant Episcribe Llc Heterocyclic compounds as PRMT5 inhibitors
AU2019212118A1 (en) 2018-01-24 2020-09-03 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
WO2019175897A1 (en) 2018-03-13 2019-09-19 Jubilant Biosys Limited Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
CN116239578B (en) * 2022-12-08 2024-09-13 中国海洋大学 Piperazine dione ring compound, synthesis method thereof and application thereof in preparation of antitumor drugs
CN116400068B (en) * 2023-02-13 2023-09-22 泉州圣源警用侦察设备有限公司 Reagent for revealing potential biological trace containing DNA and revealing method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE621862C (en) * 1932-07-01 1935-11-14 Guenther Schiemann Dr Process for the preparation of condensation products of nucleus fluorinated aryl aldehydes
GB9217331D0 (en) * 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
JPH08247357A (en) * 1995-03-13 1996-09-27 Zexel Corp Flange joint and forming method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9521832A1 *

Also Published As

Publication number Publication date
GB9402807D0 (en) 1994-04-06
JPH09509157A (en) 1997-09-16
IL112624A0 (en) 1995-05-26
GB9502874D0 (en) 1995-04-05
WO1995021832A1 (en) 1995-08-17
AU693159B2 (en) 1998-06-25
GB2286395B (en) 1998-08-26
CA2182877A1 (en) 1995-08-17
ZA951180B (en) 1996-08-14
AU1667795A (en) 1995-08-29
GB2286395A (en) 1995-08-16

Similar Documents

Publication Publication Date Title
EP0745070A1 (en) Pharmaceutical piperazine compounds
US5891877A (en) Pharmaceutical compounds
AU692836B2 (en) Pharmaceutical piperazine compounds
EP0655060B1 (en) Pharmaceutically active diketopiperazines
CA2111851C (en) (s)(+)-2-ethoxy-4-[n-{1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid
DE69830410T2 (en) META BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS
EP0760812A1 (en) Pharmaceutical diketopiperazine compounds
WO1999028297A1 (en) Substituted indoles, having a thrombin inhibiting effect
SK107293A3 (en) Carboxylic acid derivatives, drugs containing these compounds and method of their production
EP1017393A1 (en) Pyrazinone thrombin inhibitors
DE19834751A1 (en) Disubstituted bicyclic heterocycles, their preparation and their use as medicines
CA2098158A1 (en) Biphenyl derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
AU767039B2 (en) 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
WO1995021830A1 (en) Pharmaceutical piperazin compounds
US4647561A (en) 1,5-benzodiazepine compounds
DE19530996A1 (en) Cyclic guanidines, process for their preparation and pharmaceuticals
PL186851B1 (en) Derivatives of piperasino-2,5-dione as modulators of drug-fasteness in respect to many drugs
US6011038A (en) Pyrazinone thrombin inhibitors
US4312990A (en) 1-Mercaptoacyl-3-[(aminosulfonyl) phenyl]-4,5-dihydro-1H-pyrazole-5-carboxylic acid
WO1996020179A1 (en) Piperazine-2,5-dione derivatives as modulators of multi-drug resistance
US4945092A (en) Substituted 1-(oxopyrrolidinylalkanoyl)-piperazines useful as nootropics
EP0278265B1 (en) 1- [(4-Morpholinyl) alkyl] -1H-indoles useful as analgesics and preparation thereof
WO2004080970A1 (en) Novel bicyclic aromatic compounds, the production and use thereof in the form of drugs
JPH07300414A (en) Therapeutic agent for cardiac insufficiency
JPH0390083A (en) 1-substituted-1, 2-dihydro-4-((substituted) phenyl) imidazo (1, 5-a)pyrimidine-8-carbonitrile

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960802

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE ES FR GB IT NL

17Q First examination report despatched

Effective date: 19971028

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19981216